

1 **Harnessing the power of genomics in hypertension: tip of the iceberg?**

2

3

Hafiz Naderi^{1,2,3}, Helen R Warren^{1,3}, Patricia B Munroe^{*1,3}

4

1. William Harvey Research Institute, Queen Mary University of London, Charterhouse Square,
London, UK

5

6

2. Barts Heart Centre, St Bartholomew's Hospital, Barts Health NHS Trust, West Smithfield,
London, UK

7

8

3. National Institute of Health and Care Research Barts Biomedical Research Centre, Queen Mary
University of London, Charterhouse Square, London, UK

9

10

11

12

PBM (p.b.munroe@qmul.ac.uk) is the corresponding author.

13

14

15

This peer-reviewed article has been accepted for publication but not yet copyedited or typeset, and so may be subject to change during the production process. The article is considered published and may be cited using its DOI.

10.1017/pcm.2025.1

This is an Open Access article, distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives licence (<http://creativecommons.org/licenses/by-nc-nd/4.0/>), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is unaltered and is properly cited. The written permission of Cambridge University Press must be obtained for commercial re-use or in order to create a derivative work.

1 **Impact statement**

2 High blood pressure or hypertension is the strongest modifiable risk factor for cardiovascular disease,
3 and it is a complex condition influenced by both genetic and environmental factors. In this review article
4 we explore the significant milestones to our current understanding of the genetics of hypertension. We
5 highlight key landmarks in blood pressure related research from the discovery of monogenic forms of
6 hypertension to the era of genome wide association studies. Alongside the development of polygenic
7 risk scores for cardiovascular risk prediction, the application of multi-omics, single-cell RNA
8 technologies and machine learning are providing new insights into the pathophysiology of hypertension.
9 We also explore the development of pharmacogenomics in hypertension and the role of large-scale
10 biobanks in drug development together with the challenges and future landscape.

11
12
13
14
15
16
17

1 **Abstract**

2 Despite the blaze of advancing knowledge on its complex genetic architecture, hypertension remains
3 an elusive condition. Genetic studies of blood pressure have yielded bitter-sweet results thus far with
4 the identification of more than 2,000 genetic loci, though the candidate causal genes and biological
5 pathways remain largely unknown. The era of big data and sophisticated statistical tools have propelled
6 insights into pathophysiology and causal inferences. However, new genetic risk tools for hypertension
7 are the tip of the iceberg and applications of genomic technology are likely to proliferate. We review
8 the genomics of hypertension, exploring the significant milestones in our current understanding of this
9 condition and the progress towards personalised treatment and management for hypertension.

10

11

12 **Keywords**

13

14 Hypertension, Precision Medicine, Genomics

1 **The hype in hypertension**

2 Hypertension is the strongest modifiable risk factor for cardiovascular disease, being responsible for
3 the majority of stroke and up to half of cases of coronary heart disease (Perkovic et al. 2007). The global
4 health burden of hypertension is immense, with 1.5 billion people projected to be affected by 2025
5 (Kearney et al. 2005). The societal cost resulting from the morbidity and mortality caused by
6 hypertension has raised an urgent need for innovative approaches, with its prevention being a top
7 priority in governments worldwide and endorsed by the 2023 European Society of Hypertension
8 guidelines (Mancia *et al.* 2023) and the latest 2024 European Society of Cardiology guidelines (McEvoy
9 et al. 2024). The risk for cardiovascular disease attributable to blood pressure (BP) is on a continuous
10 exposure scale (Murray *et al.* 2020). Elevated BP adversely affects the heart, kidneys, brain, eyes and
11 vessels, leading to structural and functional changes termed hypertension-mediated organ damage.
12 Clinically, hypertension is diagnosed based on BP measurements, however BP is a complex trait
13 influenced by a magnitude of physiological and environmental interacting pathways. Approximately
14 95% of cases of hypertension are referred to as primary or essential hypertension (EH) with genetics
15 contributing approximately 30% of BP variance, and the remainder due to lifestyle factors (Poulter *et*
16 *al.* 2015). The other 5% of causes is termed secondary hypertension, of which 1% are monogenic
17 disorders (Cowley, 2006). Currently, pharmacological treatments for hypertension are introduced when
18 BP measurements are elevated and there is potential end organ damage initiation. The major
19 international guidelines recommend a combination of antihypertensive drugs as first-line therapy to
20 improve efficacy and reduce risk of side effects related to treatment. Challenges such as non-adherence
21 to therapy and resistant hypertension have limited the current ability to ensure adequate BP control in
22 the general population. The ‘precision hypertension’ approach has been proposed to consider an
23 individual’s unique characteristics for better targeted risk profiling and treatment strategy (Dzau and
24 Hodgkinson 2024). In this review we highlight some of the key advances (Figure 1) in hypertension
25 genomics together with its challenges and future landscape.

26

27 **The yellow brick road**

28 The concept that hypertension is a multifactorial disease was first proposed by Page’s Mosaic Theory
29 in 1949 (Page, 1949). Following evidence from familial studies and discovery of rare monogenic
30 disorders of hypertension, the genetic contribution of hypertension was recognised. The 1950s

This peer-reviewed article has been accepted for publication but not yet copyedited or typeset, and so may be subject to change during the production process. The article is considered published and may be cited using its DOI.

10.1017/pcm.2025.1

This is an Open Access article, distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives licence (<http://creativecommons.org/licenses/by-nc-nd/4.0/>), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is unaltered and is properly cited. The written permission of Cambridge University Press must be obtained for commercial re-use or in order to create a derivative work.

1 witnessed the legendary Platt vs Pickering debate on the genetic nature of EH. The controversy stemmed
2 from the appearance of BP frequency distribution curves, which led to the discussion of its monogenic
3 or polygenic potential. Platt regarded EH as a distinct condition with rare variants of hypertension as
4 evidence for its single-gene inheritance, whilst Pickering postulated that hypertension was seen only in
5 the extreme of a continuous distribution curve of BP values and therefore determined by a collection of
6 genes (Zanchetti 1986; Brown 2012). Later studies supported the polygenic theory of hypertension with
7 a wide range of heritability estimates for systolic and diastolic BP from 6% to 68% (Kolifarhood et al.
8 2019). Differences in environmental conditions, type of study design, trait definition, and analytical
9 techniques may explain the wide variation in heritability estimation of BP traits. In light of the new
10 evidence, Page also acknowledged the genetic influence of hypertension in his revision of the Mosaic
11 Theory in 1982 (Page 1982). The 1990s saw the big boom in gene mapping with the launch of The
12 Human Genome Project sequencing the complete human genome by 2003 (International Human
13 Genome Sequencing Consortium 2004). During this period there were a number of genome wide
14 linkage analyses performed, including the Framingham Heart Study and the British Genetics of
15 Hypertension (BRIGHT) study, identifying regions in the DNA linked to variations in BP (Levy *et al.*
16 2000; Caulfield *et al.* 2003). Although an important step, interpreting results from linkage analyses
17 proved challenging, as the regions in the DNA identified were large, hence difficult to identify the
18 responsible gene. The turn of the millennium welcomed a wave of advancing technology and
19 bioinformatics, paving the way for the era of genome wide association studies (GWAS).

20

21 **GWAS for Blood Pressure**

22 The hunt for genes implicated in BP regulation has been challenging. Before the advent of GWAS,
23 genes and mechanisms for BP were mostly discovered using rat and mouse models and candidate gene
24 studies (Lerman *et al.* 2019). Since the launch of single-nucleotide polymorphism (SNP) genotyping
25 arrays in 2005, BP-GWAS of increasing scale have been performed. The first GWAS of hypertension
26 was performed in 2007 by The Wellcome Trust Case Control Consortium (WTCCC). This consortium
27 undertook GWAS of 2,000 cases and 3,000 shared controls for seven complex diseases, including
28 hypertension (Wellcome Trust Case Control Consortium 2007). Although no single SNP achieved
29 genome-wide significance ($P < 5 \times 10^{-7}$), six variants were found to have suggestive associations with
30 hypertension ($P < 5 \times 10^{-5}$). The Family Blood Pressure Program (FBPP) subsequently focussed on
31 these six SNPs in a study of 11,433 individuals recruited from hypertensive families. This study did not
32 replicate the results of the WTCCC study, however one of the six SNPs (rs1937506) was found to be
33 associated with hypertension in Hispanic Americans and European Americans (Ehret et al. 2008).
34 Subsequently, investigators from the Korean Association Resource (KARE) project analysed the
35 association of the six SNPs in 7,551 unrelated individuals in Korea. The authors reported one intronic
36 SNP (rs7961152 at the *BACT1* gene locus) to be associated with hypertension risk (odds ratio 1.29,
37 95% Confidence Interval 1.01-1.64, $P=0.004$) (Hong et al. 2009). The WTCCC, FBPP and KARE

1 studies demonstrated that due to the complex genetic architecture of hypertension, a larger sample
2 population may be necessary to identify genetic variants implicated in BP. To increase the sample
3 sizes, consortia were established, to combine data together across many different studies. The first
4 exciting results in BP-GWAS were in 2009 from large meta-analyses of GWAS ($n=34,433$) from the
5 Global BP Genetics Consortium (GBPGEN) and Cohorts for Heart and Ageing Research in Genomic
6 Epidemiology-BP (CHARGE-BP) consortium, identifying 11 new loci (Levy *et al.* 2009; Newton-Cheh
7 *et al.* 2009; Psaty *et al.* 2009). Seven of these loci were also subsequently reported in a Japanese
8 population (Takeuchi *et al.* 2010). Following this success story, the two consortia GBPGEN and
9 CHARGE-BP merged to form the International Consortia for BP (ICBP) identifying more novel loci in
10 2011 (Wain *et al.* 2011; Ehret *et al.* 2011). Cho *et al.* (2009) also reported 5 new BP loci in East Asians
11 (Cho *et al.* 2009). The results from these studies provided new insights into the biology of BP with
12 opportunities for developing new therapies

13

14 **Big data, biobanks and beyond**

15 Over the past decade, large-scale datasets have been developed, one example is the UK Biobank,
16 permitting analysis in up to 500,000 richly phenotyped participants (Bycroft *et al.* 2018). Leveraging
17 these resources, Warren *et al.* (2017) performed the first UK Biobank BP-GWAS for the first 150,000
18 genotyped participants (Warren *et al.* 2017). Hoffman *et al.* (2017) performed a GWAS on long term
19 average BP from the electronic health records on 99,785 individuals identifying 39 new loci (Hoffmann
20 *et al.* 2017). Once all the UK Biobank data became available, Evangelou and colleagues (2018)
21 performed GWAS meta-analyses including data from both the UK Biobank and ICBP, and identified
22 535 new genetic loci influencing BP (Evangelou *et al.* 2018). Alongside the GWAS for common
23 variants for BP, there has also been large-scale consortium-based studies focused on the discovery of
24 rare variants across many meta-analysed studies, including UK Biobank (minor allele frequencies of
25 $<1\%$) (Surendran *et al.* 2020). These studies have yielded >80 rare variants, all having larger effects on
26 BP ($\sim 1.5\text{mmHg}$ per allele, compared to $\sim 0.5\text{mmHg}$ for common variants) (He *et al.* 2022).

27

28 Additional large biobanks, include the Million Veteran Program (MVP, $n \sim$ currently recruiting and
29 with 635,969), which has created one of the largest epidemiologic research infrastructures embedded
30 within the national health care system operated by the US Department of Veteran Affairs, these data
31 have also been used for BP-GWAS (Giri *et al.* 2019; Verma *et al.* 2024). Other notable cohorts
32 projected to deliver population-level genomic insights include: Genomics England's first initiative, the
33 100,000 Genomes Project identifying the genetic causes of many rare diseases; and FinnGen, a Finnish
34 biobank of 500,000 participants (100,000 Genomes Project Pilot Investigators *et al.* 2021; Kurki *et al.*
35 2023).

36

1 The majority of GWAS studies for BP did not initially consider the precise role and biological
2 significance of gene-environment interactions (GxE). To address this gap in knowledge, the CHARGE
3 Gene-Lifestyle Interactions Working Group was formed, and this group has conducted a series of
4 genome-wide interaction studies for various traits and exposures. Recently, the group examined
5 interactions between genotype and the Dietary Approaches to Stop Hypertension (DASH) diet score
6 and systolic BP (Guirette *et al.* 2024). They demonstrated gene-DASH diet score interaction effects on
7 systolic BP in several loci in European population-specific and cross-population meta-analyses.
8 Additional studies have investigated several other important lifestyle factors, including a study
9 investigating BP x Alcohol, which found 54 loci; and BP x Smoking which found 15 loci (Sung *et al.*
10 2018; Feitosa *et al.* 2018). These studies included ~130,000 individuals across multi-ancestry data-sets,
11 but there were limited findings, and analyses in larger sample sizes are currently ongoing.

12

13 **Polygenic risk score and cardiovascular risk prediction**

14 As GWAS results become publicly available, this has enabled risk prediction modelling to include
15 genetic biomarkers for clinical applications. BP is a highly polygenic trait, influenced by thousands of
16 different SNPs each of which has a small effect on BP. Polygenic risk scores (PRS) have been developed
17 by combining the risk associated with many common DNA sequence variants into one single
18 aggregated risk score (Lewis and Vassos 2020). The first genetic risk score for BP was developed by
19 the ICBP in 2011 by combining together 29 different significant genetic variants into one score (Ehret
20 *et al.* 2011). The identification of further BP loci has led to the development of PRS with increasing
21 performance to estimate an individual's risk of hypertension. For example, in 2022, Parcha et al
22 developed and tested a BP-PRS in a multi-ancestry US cohort (n=21,897) to evaluate the relative
23 contributions of the traditional cardiovascular risk factors to the development of adverse events in the
24 context of varying BP risk profiles in individuals with no previous cardiovascular disease. They
25 demonstrated that the PRS had an incremental value beyond traditional risk factors highlighting the
26 potential of incorporating genetic information into risk estimates (Parcha *et al.* 2022). Recently, Keaton
27 and colleagues (2024) performed the largest single-stage BP GWAS to date (n=1,028,980 European
28 ancestry individuals), reporting a total of 2,103 independent genetic signals for BP. The BP-PRS
29 generated from this study revealed clinically meaningful differences in BP (16.9 mmHg systolic BP,
30 95% CI=15.5-18.2 mmHg, $P=2.22 \times 10^{-126}$) and more than a seven-fold higher odds of hypertension risk
31 (OR=7.33; 95% CI=5.54-9.70; $P=4.13 \times 10^{-44}$), when comparing individuals in the top (highest genetic
32 risk) versus bottom (lowest risk group) deciles of the PRS in an independent European cohort, Lifelines.
33 The authors also showed that the BP-PRS was significantly associated with higher BP in individuals of
34 African-American ancestry from the All-of-Us Research program in the United States (Keaton et al.
35 2024).

36

1 As part of the study design for the large meta-analyses for BP-GWAS, the impact of biological sex has
2 been understudied, thus results are limited on assessing differences between sexes. Kauko and
3 colleagues (2021) developed a sex-specific PRS in FinnGen (N=218,792) and found the female PRS
4 was more strongly associated with hypertension in women than the male PRS in men (Kauko *et al.*
5 2021). Similarly, Shetty et al (2023) developed sex-specific systolic BP-PRS in UK Biobank and tested
6 for associations of developing hypertension in 212,669 participants in the All of Us study. They found
7 the genetic risk of systolic BP was more strongly associated with female PRS (Shetty *et al.* 2023).
8 Recently, Yang et al (2024) performed sex-stratified GWAS analyses of BP traits in the UK Biobank
9 resource, identifying 1,346 previously reported and 29 new BP trait-associated loci. Despite equal
10 sample sizes, sex-stratified GWAS of systolic BP, diastolic BP and pulse pressure identified 1.8-fold
11 more loci in the female-only analyses (N=174,664) than in the male-only analyses (N=174,664). These
12 sex-specific loci were enriched for hormone-related transcription factors, in particular, oestrogen
13 receptor 1, and sex-specific polygenic association of BP traits were associated with multiple
14 cardiovascular traits (Yang *et al.* 2024).

15

16 Integration of PRS for early disease risk prediction is an area of active research, and with increased
17 number of loci being found for complex diseases, the percentage of the heritability explained is
18 increasing, and better PRS are being developed (Ge *et al.* 2019). With increasing datasets being
19 recruited of non-European ancestry, new loci discovery and population specific PRS are being
20 developed (Fujii *et al.* 2024). Genomics PLC have sought to integrate PRS to re-engineer prevention
21 strategies in healthcare for commercial exploitation (Genomics PLC). In their trial, Fuat and colleagues
22 (2024) enrolled 832 participants across 12 UK primary care practices. They observed that the
23 integration of genetic data to a conventional risk algorithm (QRISK2) for cardiovascular disease was
24 accepted by health care professionals and participants in primary care with planned changes in
25 prevention strategies (Fuat *et al.* 2024). These risk prediction tools are a funnel for personalised
26 medicine with potential for population level risk stratification. However, currently it is unclear how this
27 genetic information is best integrated into guideline-recommended risk prediction tools. One of the
28 main weaknesses of PRS is that they report genetic risk relative to a given population, thus their
29 contribution is only meaningful in the context of other risk factors, limiting their clinical applicability
30 (Ding *et al.* 2021; Abramowitz *et al.* 2024).

31

32 GWAS provides candidate genes, disease mechanisms and PRS for assessing relationships between BP
33 and other traits. The PRS however do not provide information on whether there are causal relationships.
34 Mendelian randomization (MR) is being widely applied to infer causality using genetic data, with power
35 equivalent to that of a randomized controlled trial, overcoming traditional bias attributed to confounders
36 and reverse causation (Burgess *et al.* 2012). There have been several applications of BP in a MR
37 framework (Nazarzadeh *et al.* 2019; Tang *et al.* 2023). In an MR study by Clarke et al (2023), higher

1 levels of genetically predicted systolic BP associated with higher risks of major cardiovascular disease
2 in the range of 120 to 170 mm Hg of participants in the China Kadoorie Biobank (Clarke *et al.* 2023).
3 The associations of lower genetically-predicted systolic BP with lower risks of cardiovascular outcomes
4 down to 120 mmHg challenges the conventional strategy of restricting the initiation of BP-lowering
5 medication to people with systolic BP ≥ 140 mm Hg. These findings provide support for lowering
6 systolic BP for a wider range of the population down to 120 mmHg.

10 **From omics to AI for gene identification**

11 Advances in multi-omics technologies have provided new insights into the pathophysiology of
12 hypertension. The omics approaches target different molecular levels, including the genome,
13 transcriptome, proteome, metabolome and microbiome, providing a comprehensive assessment of the
14 processes by which DNA is transcribed into RNA that is translated into proteins that regulate
15 downstream metabolism. These novel datasets can provide valuable insights into the mechanisms of
16 hypertension, allowing for better understanding of its pathogenesis and aiding the clinical needs of early
17 diagnosis and monitoring of the treatment response. Several computational approaches have been used
18 to prioritise candidate genes leveraging multi-omic datasets, with most groups using the GWAS results
19 from the 2018 Evangelou *et al* study (Evangelou *et al.* 2018). For example, Eales *et al* (2021) integrated
20 genotype, gene expression, alternative splicing and DNA methylation profiles of up to 430 human
21 kidneys to characterise the effects of BP SNPs from GWAS on renal transcriptome and epigenome
22 (Eales *et al.* 2021). Sheng and colleagues created maps of expression quantitative trait loci (eQTLs) for
23 659 kidney samples and identified cell-type eQTLs, and integrated GWAS results with single cell RNA
24 sequencing (scRNA-seq) and a single-nucleus assay for transposase-accessible chromatin with high-
25 throughput sequencing, a method for identifying regulatory elements in specific cell types. Their study
26 indicated 200 genes for kidney function and hypertension, and highlighted endothelial cells and distal
27 tubules as being important for BP (Sheng *et al.* 2021). More recently, Ganji-Arjenaki *et al* (2024)
28 leveraged the largest GWAS of BP traits with scRNA-seq from 14 mature human kidneys and
29 prioritised myofibroblasts and endothelial cells among the 33 annotated cell types involved in BP
30 regulation (Ganji-Arjenaki *et al.* 2024). Other efforts include van Duijvenboden and colleagues (2022)
31 who conducted annotation-informed fine-mapping incorporating tissue specific chromatin
32 segmentation and colocalization using transcriptomics and additional gene prioritisation utilising both
33 scRNA-seq and proteomics datasets to identify causal variants and candidate effector genes for BP
34 traits (Duijvenboden *et al.* 2023). Kamali *et al* (2022) also developed a pipeline to leverage epigenomic
35 and transcriptomic datasets and identified 1,880 prioritised genes for BP and downstream from this, the
36 genes were assessed for druggability and tested for functional enrichment (Kamali *et al.* 2022). The
37 different approaches have highlighted many BP genes for follow up studies.

1
2 Machine learning (ML) approaches have also been used to prioritise candidate genes discovered
3 through GWAS. ML algorithms build mathematical models that are learnt from training data to make
4 predictions. ML in GWAS has been used to boost statistical power of GWAS, refine PRS produced
5 from GWAS and prioritise candidate genes on post-GWAS-analysis (Li *et al.* 2017; Nicholls *et al.*
6 2020). Additionally, multi-parallel functional experiments have also been applied to gain insights into
7 causality and related molecular mechanisms of genetic variants derived from GWAS. Oliveros and
8 colleagues (2023) functionally characterised 4,608 genetic variants in linkage with SNPs at 135 BP loci
9 in vascular smooth muscle cells and cardiomyocytes using parallel reporter assays. This approach
10 demonstrated potential to identify functionally relevant variants for better understanding of BP genetic
11 architecture (Oliveros *et al.* 2023).

12

13 **Pharmacogenomics, therapeutics and druggability**

14 Genetics research has promoted the discipline of pharmacogenomics exploring the influence of
15 genomic variation to an individual's response to BP therapy (Rodén *et al.* 2019). This is particularly
16 necessary for hypertension as there is a large proportion of individuals who do not respond to current
17 treatments. The development of new drug treatments is therefore one key driver of BP genomics and
18 exploring potential for drug repurposing. Evangelou *et al.* (2018) discovered five loci containing genes
19 which are drug targets for several known antihypertensive classes and Surendran and colleagues (2020)
20 reported 23 genes as potential drug targets (Evangelou *et al.* 2018; Surendran *et al.* 2020). Similarly,
21 Keaton *et al.* (2024) used transcriptome-wide association studies (TWAS) to identify 38 genes, including
22 an established drug target for BP medications (*ADRA1A*) and five genes targeted by other approved
23 drugs (Keaton *et al.* 2024). However, as previously described, GWAS and downstream bioinformatics
24 analyses do not pinpoint the causal gene, they only provide candidates for further exploration.
25 Functional cellular studies and development of animal models remain an important tool once a gene is
26 identified as having strong potential as a druggable target.

27

28 Drug-gene interaction databases have enabled a comprehensive catalogue of druggable genes (Gaulton
29 *et al.* 2017; Cotto *et al.* 2018). These open-access online resources have allowed a search by gene of
30 drug gene interactions or potential for druggability. Canagliflozin, an SGLT2 inhibitor, is an approved
31 and widely used medication in the treatment of type 2 diabetes targeting the gene *SLC5A1*. However, it
32 was noted that it reduced systolic BP in individuals with type 2 diabetes and chronic kidney disease,
33 providing end-organ protection for this cohort of patients who experience a high burden of hypertension
34 (Ye *et al.* 2021). Although it is currently not licenced for BP treatment, it highlights the repurposing
35 potential of existing drugs.

36

1 The most common distinct cause of hypertension is primary hyperaldosteronism, also known as Conn's
2 syndrome. It has been shown that some patients with treatment resistant hypertension, defined as
3 uncontrolled, high BP despite being on three or more different antihypertensive drug classes, have
4 increased aldosterone production. Baxdrostat, an aldosterone synthase inhibitor, targets the gene
5 *CYP11B2*, which encodes aldosterone synthase in the adrenal gland. The *CYP11B2* candidate gene was
6 found to be genome-wide significant in BP-GWAS of Japanese individuals by Kanai *et al.* (2018) and
7 also in subsequent European ancestry BP-GWAS (Keaton *et al.* 2024). It is a once daily oral medication
8 currently under study with promising phase 2 clinical trial results, which may expand the possible
9 choices of therapeutic agents for treatment-resistant hypertension (Freeman *et al.* 2022).

10
11 The biological architecture of hypertension is complex, and existing medications target only specific
12 mechanisms in BP regulation, with variable effectiveness across individuals (Thomopoulos *et al.* 2015).
13 The development of gene-editing and RNA-based approaches have inspired new treatment modalities
14 for hypertension. These techniques allow selective and organ-specific modulation of systems involved
15 in BP regulation. Antisense oligonucleotides (ASO) and small interfering RNA (siRNA) have been
16 used to specifically target the hepatic angiotensinogen (AGT) production, with the scope of effectively
17 downregulating the activation of the renin-angiotensin system (Masi *et al.* 2024). These approaches
18 have the potential to simplify BP treatment regimens with weekly, monthly or even once-only injection
19 of the drugs. Among the various technologies, siRNA and ASO that reduce hepatic AGT production
20 are currently in advanced development, with phase I and II clinical trials showing their safety and
21 effectiveness (Desai *et al.* 2023; Bakris *et al.* 2024). The CRISPR (clustered Regularly Interspaced
22 Short Palindromic Repeats) and its associated protein Cas9 is another gene editing tool and the first
23 CRISPR-based human therapy was approved in 2023 for sickle cell disease and β -thalassaemia (Wong
24 2023). CRISPR-Cas9 gene editing technology has also been utilised in hypertension research in animal
25 models (Cheng *et al.* 2017; Sun *et al.* 2021). The application of gene-editing may be an avenue for
26 treating single-gene causes of hypertension. Examples of monogenic hypertension include Liddle
27 syndrome (epithelial sodium channel gain of function), Gordon syndrome (gain of function in 4 genes
28 regulating Na-K-Cl cotransporter activity), mineralocorticoid excess (11- β -hydroxysteroid
29 dehydrogenase type II loss of function), and glucocorticoid-remediable aldosteronism (crossover of
30 adjacent genes, *CYP11B1* and *CYP11B2* as previously mentioned) (Zappa *et al.* 2024). Monogenic
31 forms of hypertension are typically associated with early onset, severe, and resistant hypertension. In
32 cases of monogenic hypertension, where a single gene mutation follows Mendelian inheritance
33 patterns, gene-editing may offer a cure to the disease.

34 35 **Challenges and future landscape**

36 High-throughput next-generation sequencing technologies continue to evolve, and the cost of whole
37 genome sequencing is continuing to fall. This will increase datasets for dissection of causal genes, BP

1 mechanisms and data for inclusion in risk score algorithms. There are many different ethical issues
2 raised by genomic research. Ancestral bias is an important consideration as most genetic data acquired
3 to date has been predominantly from individuals of European ancestry. Individuals of African ancestry
4 have the highest age-adjusted prevalence of hypertension but are relatively under-represented in BP
5 genetic studies (Franceschini *et al.* 2013). An increase in diverse sampling is being addressed by
6 ongoing efforts of national biobanks which are being used to discover novel and ancestry-specific loci
7 within e.g. Japan, Asia, Africa and Qatar (Genome Research Biobank Project Biobank Japan;
8 GenomeAsia; H3Africa – Human Heredity & Health in Africa; Qatar Biobank). Despite these efforts
9 to increase genetic diversity and representation, there is still more to be done. Bridging this data gap is
10 crucial for equitable genomic testing and ensuring GWAS results are beneficial across populations, and
11 that we avoid reinforcing existing health disparities. Furthermore, genomic data can reveal sensitive
12 information about an individual and their family’s ancestry and health. It is therefore important that
13 biobanks store and provide approved researchers with access to genomic data securely and responsibly.
14 There are also ethical considerations in incorporating genetic risk stratification with implications in the
15 insurance sector. An important step in implementing ethical and governance frameworks which balance
16 these risks will be to ensure that any procedures command public trust.

17

18 Demographic changes with the ageing population and increased multimorbidity pose challenges to
19 hypertension management. To date, genomic research in hypertension has been largely focused on
20 aiding diagnosis (especially for monogenic forms of hypertension) and identifying potential target
21 mechanisms for treatment. The next wave of genomics in hypertension has the potential to empower a
22 preventive approach with effective screening at population scale. Our Future Health, the flagship UK
23 programme with the National Health Service, highlights a strategic partnership between industry,
24 academia, and government together with patients and the public to support preventive approaches to
25 tackling common diseases (Our Future Health). The programme combines clinical and genetic data to
26 calculate disease risk scores with the aim of targeting individuals who are at higher risk of developing
27 certain diseases. This will provide an opportunity to test the potential of new polygenic risk scores in
28 health care and of new diagnostic tests or treatments to see how effective they could be for people at
29 higher risk of certain diseases. These collaborations demonstrate that the long-term applications of
30 genomic technology are likely to proliferate beyond genetic risk tools. New use cases are appearing and
31 will revolutionise healthcare delivery through improved differential diagnosis with genetics and
32 personalised medication selection, optimising safety and efficacy. These hold promise for implementing
33 predictive, personalised and preventive approaches to hypertension management that is enduring.
34 Central to the effective delivery of precision medicine in hypertension is patient and public
35 involvement. A focus on a person-centred approach with emphasis on patient perspective in research,
36 guidelines and scientific documents ensures that the patient is at the heart of all that we do.

Landmarks in hypertension genomics




Figure 1: Key advances in hypertension genomics.

1 **Acknowledgements**

2 Graphical abstract was created using Procreate.com.

3

4 **Author contributions**

5 HN wrote the manuscript. HRW and PBM critically reviewed and approved the manuscript.

6

7 **Sources of funding**

8 HN acknowledges the National Institute for Health and Care Research (NIHR) Integrated Academic
9 Training Programme, which supports his Academic Clinical Lectureship post (CL-2024-19-002). PBM
10 and HRW acknowledge support from the National Institute for Health and Care Research (NIHR)
11 Biomedical Research Centre at Barts (NIHR202330).

12

13 **Conflicts of interest.**

14 None to declare.

15

1 **References**

- 2 100,000 Genomes Project Pilot Investigators, Smedley D, Smith KR, Martin A, Thomas EA,
3 McDonagh EM, Cipriani V, Ellingford JM, Arno G, Tucci A, Vandrovцова J, Chan G,
4 Williams HJ, Ratnaïke T, Wei W, Stirrups K, Ibanez K, Moutsianas L, Wielscher M,
5 Need A, Barnes MR, Vestito L, Buchanan J, Wordsworth S, Ashford S, Rehmström K,
6 Li E, Fuller G, Twiss P, Spasic-Boskovic O, Halsall S, Floto RA, Poole K, Wagner A,
7 Mehta SG, Gurnell M, Burrows N, James R, Penkett C, Dewhurst E, Gräf S, Mapeta R,
8 Kananicki M, Haworth A, Savage H, Babcock M, Reese MG, Bale M, Baple E, Boustred
9 C, Brittain H, de Burca A, Bleda M, Devereau A, Halai D, Haraldsdottir E, Hyder Z,
10 Kasperaviciute D, Patch C, Polychronopoulos D, Matchan A, Sultana R, Ryten M,
11 Tavares ALT, Tregidgo C, Turnbull C, Welland M, Wood S, Snow C, Williams E, Leigh S,
12 Foulger RE, Daugherty LC, Niblock O, Leong IUS, Wright CF, Davies J, Crichton C,
13 Welch J, Woods K, Abulhoul L, Aurora P, Bockenbauer D, Broomfield A, Cleary MA,
14 Lam T, Dattani M, Footitt E, Ganesan V, Grunewald S, Compeyrot-Lacassagne S,
15 Muntoni F, Pilkington C, Quinlivan R, Thapar N, Wallis C, Wedderburn LR, Worth A,
16 Bueser T, Compton C, Deshpande C, Fassihi H, Haque E, Izatt L, Josifova D,
17 Mohammed S, Robert L, Rose S, Ruddy D, Sarkany R, Say G, Shaw AC, Wolejko A,
18 Habib B, Burns G, Hunter S, Grocock RJ, Humphray SJ, Robinson PN, Haendel M,
19 Simpson MA, Banka S, Clayton-Smith J, Douzgou S, Hall G, Thomas HB, O'Keefe RT,
20 Michaelides M, Moore AT, Malka S, Pontikos N, Browning AC, Straub V, Gorman GS,
21 Horvath R, Quinton R, Schaefer AM, Yu-Wai-Man P, Turnbull DM, McFarland R,
22 Taylor RW, O'Connor E, Yip J, Newland K, Morris HR, Polke J, Wood NW, Campbell C,
23 Camps C, Gibson K, Koelling N, Lester T, Németh AH, Palles C, Patel S, Roy NBA, Sen
24 A, Taylor J, Cacheiro P, Jacobsen JO, Seaby EG, Davison V, Chitty L, Douglas A, Naresh

1 K, McMullan D, Ellard S, Temple IK, Mumford AD, Wilson G, Beales P, Bitner-Glindzicz
2 M, Black G, Bradley JR, Brennan P, Burn J, Chinnery PF, Elliott P, Flinter F, Houlden H,
3 Irving M, Newman W, Rahman S, Sayer JA, Taylor JC, Webster AR, Wilkie AOM,
4 Ouwehand WH, Raymond FL, Chisholm J, Hill S, Bentley D, Scott RH, Fowler T,
5 Rendon A and Caulfield M (2021) 100,000 Genomes Pilot on Rare-Disease Diagnosis
6 in Health Care - Preliminary Report. *The New England Journal of Medicine* 385(20),
7 1868–1880. <https://doi.org/10.1056/NEJMoa2035790>.

8 Abramowitz SA, Boulier K, Keat K, Cardone KM, Shivakumar M, DePaolo J, Judy R, Bermudez
9 F, Mimouni N, Neylan C, Kim D, Rader DJ, Ritchie MD, Voight BF, Pasaniuc B, Levin
10 MG, Damrauer SM, BioBank PM, Rader DJ, Ritchie MD, Weaver J, Naseer N, Sirugo G,
11 Poindexter A, Ko Y-A, Nerz KP, Livingstone M, Vadivieso F, DerOhannessian S, Tran T,
12 Stephanowski J, Santos S, Haubein N, Dunn J, Verma A, Kripke CM, Risan M, Judy R,
13 Wollack C, Verma SS, Damrauer SM, Bradford Y, Dudek S and Drivas T (2024)
14 Evaluating Performance and Agreement of Coronary Heart Disease Polygenic Risk
15 Scores. *JAMA*. <https://doi.org/10.1001/jama.2024.23784>.

16 Bakris GL, Saxena M, Gupta A, Chalhoub F, Lee J, Stiglitz D, Makarova N, Goyal N, Guo W,
17 Zappe D, Desai AS, Group K-1 S, Carr G, Case C, Jaeger L, Bruns L, Stratman G, Kidwell
18 C, Cunningham S, Piccone N, Klein M, Acuna M, Arora S, Clark A, Fink E, Garcia C,
19 George A, Gray E, Mahaffey C, McElheney M, Ortiz E, Saumya S, Wallace A, Watts J,
20 Zambrana D, Denham D, Rivera E, Aworo A, Hedges P, Fancher C, Abadier R, Braud
21 L, Cenatiempo L, Elwood A, Gray L, Gray P, Griffin K, Khan H, Kongquee N, LaTorraca
22 S, Liles T, Livingston J, Lozano M, Lupton A, Lyles T, Mardini D, Moss S, Packer K,
23 Patel A, Russ T, Scinicariello B, Trull S, Warren B, Chalhoub F, Angel S, Dhakhwa S,
24 Gabon I, Goodwin L, Jones NJ, Joyce M, Kamble N, McFall B, Githiiyu R, Robinson L,

1 Tomlinson L, Hadziavdic E, Vega S, Greenwald J, Achan J, Ruiz L, Buksh M, Chauhan
2 O, Derisseau E, Ferguson F, Grabowski M, Gumerova L, Hernandez M, Martin K, Patel
3 K, Nanda D, Perez J, Ribeca C, Rueda E, Guth AS, Zaki N, Green E, Mondoc N, Buynak
4 R, Andree S, Brazinsky M, Fuller L, Green N, Ibrahim H, Idowu M, Lee M, Lewis E,
5 Luna G, McNeal R, Owens A, Perez C, Petty T, Smith M, Volom P, Webb A, Williams
6 D, Yarosz M, Gabra N, Andrawis N, Aziz A, Hanna M, Manalo J, Helow V, Davila W,
7 Crisp S, Douglas Y, Everett J, Graham S, Heard E, Mackie M, Mayer S, Moore L,
8 Resurreccion S, Sidey J, Stephens M, Strickland M, Camp DV, Wilder S, Witt A, Wolfer
9 J, Groben L, Aeschliman L, Audlehelm E, Fitz C, Greene J, Hippen E, Johnson M,
10 Latcham A, Leggett S, Link K, Lovell J, Marlow K, Marske C, Maxwell K, Newsom-
11 Henderson C, Oelberg D, Ollinger K, Risius R, Ryther K, Waddell A, Zellerman T,
12 Santofimio MA, Plantholt S, Beatty M, Blubaugh H, Bootz T, Cole J, Conners J,
13 Coombs V, Goddard C, Ince C, Kiddy G, Klimuszka B, Kuhn F, Lowry D, Preville P, Rioux
14 S, Scott J, Shepherd B, Urffer A, Smiley S, Lucksinger G, Alvord A, Anderson J, Block C,
15 Chan A, Delgado J, Frost K, Gadbois L, Hamlin D, Johnson S, Juncal V, Kelly K, Kelly E,
16 Kelly L, Kerwin A, Kuehl A, Ostovar J, Rackley R, Rocha G, Sandberg L, Sheghewi S,
17 Smith T, Taucher B, Vasquez C, Rodriguez FV, Weisbart J, Wescom V, Williams K,
18 Overcash JS, Anorve A, Asmann H, Bovee G, Castillo L, Chu H, Coslet J, Davis A, Dinan
19 M, Dubbula A, Esparza J, Foster A, Garcia A, Gonzales J, Gonzalez L, Kappen P,
20 Kornblatt A, Lauderdale B, Lee K, Lindholm S, Lindsay A, Gomez LL, Marquez A, Meza
21 C, Odom S, Orel M, Pselio S, Penziner S, Pu H, Quillin K, Ramirez C, Ramirez R,
22 Salgado M, Shores M, Taitingfong R, Tande J, Tuiletufuga V, Tyler K, Vega L, Zepeda
23 K, Anderson C, Carhill N, Clark B, Dean L, Devine N, DiPeri S, Espinal G, Hawkins R,
24 Irra G, Ledezma A, Lopez-Wood G, Luna M, Mansour W, Marriott T, Perez A, Ramsey

1 J, Reedy W, Spinks H, Tanori C, Tatelbaum D, Vasquez R, Vasquez K, Vigil J, Worthen
2 I, Yu D, Zuniga J, Dennis P, Alvarado L, Cox A, Cullaro V, Dunbar J, Giorlando K,
3 Hannan L, Hastings T, Hoskins G, Krambeck E, Laurent J, Martinez OM, Mister R,
4 Moss A, Muli M, Quinn N, Reed B, Robinson A, Saavedra C, Simon C, Smith D,
5 Touchet D, Wright A, Trevino M, DeVries B, Allison-Hicks S, Light T, Rubach W, Mai K,
6 Osborn T, Sheets L, Carver D, Reichman A, Lotfi D, Berrios N, Vulichi S, Naguleswaran
7 T, Subhan Y, Rios M, Baron D, Khowaja A, Nair S, Vicente M, Gomez LLG, Gomez USA,
8 Lamichhane J, Ekomoda E, Nair A, Maldonado S, Naqvi M, Dayani F, Patro S,
9 Golandaz L, Jaka A, Rios S, Gurung M, Gongloor P, Coreas D, Demir T, Celik Z, McGill
10 L, Usdan L, Arnold V, Heckle K, Scatamacchia C, Anthony C, Marsh C, Fair J, Stewart
11 A, Hamlet R, Presley R, Granberry C, Flowers M, Houpt C, O'Brien D, Evans K,
12 Williams M, Sinatra J, Powell I, Flagg T, Pipkin L, Wheeler V, Wells E, Gruber B, Jones
13 A, Toor M, Iskiwitz K, Boyd M, Epps S, Cole F, Grayson-Mathis C, Web M, Turner C,
14 Reese K, Robinson D, Goodwin A, Parker K, Ward C, Solomon A, Lawson T, Pledger
15 M, Peterson AL, Carignan M, Oguoma-Richards D, Jones S, McFarland-Head K,
16 Bundeff B, Wojtowicz S, Holland C, Sanders T, Simon L, Lawrence C, Bolton B,
17 Lemoine K, Harris K, Kingsley H, Bryant D, Clawson K, Murphy C, Allison DC, Newman
18 G, Preece D, Zook P, Roznos T, Russell S, Rodriguez R, Roy A, Layle S, Mehra P, Bowen
19 S, Johnson D, Guillen N, Leone S, McCormick G, Hermann L, Sarno L, Abellatif T,
20 Cleghorn M, Elansary A, Israel A, Leeward M, Parra C, Harris S, Patel P, Cawley M,
21 Castro M, Miroshnikova T, Dever M, Venereo J, Paez H, Isla A, Martin Y, Fernandez A,
22 Hernandez I, Lavoy AI, Rios N, Hernandez A, Denenberg M, McTier T, Reynolds C,
23 Thomas L, Eubanks C, Oliver T, Jacobs M, Mirkil V, Menasche K, Yee M, Vasquez BA,
24 Garcia C, Elio L, Arenas A, Buena C, Garcia C, Cannon M, Novotny E, Oliver M, Cannon

1 A, Gatdula M, Gillenwater C, Rafi A, Derian W, Ramsey M, Culbreth E, Fessler C,
2 Sorrill K, Mauri M, Rosen J, Acosta O, Brauchle W, Castaneda D, Castells M, Castro D,
3 Laplace MBC, Flerisme M, Garcia R, Gomez J, Hidalgo M, Jimenez G, Legon M, Lella V,
4 Lemus K, Rico-Aramillo S, Rodriguez M, Rodriguez Y, Salazar L, Santana C, Tercero N,
5 Martin EE, Acevedo M, Anderson A, Baig T, Baker R, Basrai R, Cabrera N, Carroll C,
6 Chatmon S, Cheema S, Chowdhry A, Cordero N, Deandres C, Deshpande M, Dileep A,
7 Dolfi K, Eng L, Fountain N, Gali R, Hernandez A, Iskandar A, Khan R, Knight A,
8 Kundapati S, Lobo I, Lokhandwala Z, Lokhandwala Z, Mahmood F, Mareidiya R,
9 Martin EF, Melendez M, Moosa A, Motiwala A, Muhebb S, Murray M, Rehman M,
10 Rivera A, Shah A, Solorzano S, Somani L, Soneira L, Starr A, Thompson D, Torres A,
11 Tran E, Ullah MA, Valentine A, Vaquerano L, Yake A, Yousif Y, Zaldivar A, Byars W,
12 Brown H, Gaskin AC, Clayton C, Davis C, Dillon S, Driggers B, Ferrell A, Green DE, Hunt
13 L, Jeffers C, Kirkland C, Lopez L, Mayfield R, Mercer C, Parsons K, Patton S, Puck K,
14 Restrepo L, Sheppard T, Teachman G, Velez J, Whitehead A, Jain M, Asanji G, Garrett
15 J, Gill K, Hester D, Jain B, Mitchell Y, Becker T, McKeown-Biagas C, Fragoso V,
16 Holloway L, Kowalski T, Barr S, Colville B, Yang C-H, Glasper D, Phuah A, Miller V,
17 Schmidt S, Jafri A, Sureshbabu W, Mir L, Sharma S, Asaad S, Hasnain M, Ngo T, Hari
18 D, Oheri I, Patwary A, Mohamed M, Hernandez P, Gioia J, Dalal A, Ngban P, Smith S,
19 Leal BM, Assaf A, Martinez A, Khan K, Castello J, Potapenko M, Wahaj Z, Elmachtoub
20 F, Akhtar A, Siddiqui MA, Jamal M, Rizvi M, Sainz K, Lucky-Dania S, Villarreal S,
21 Fernandez W, Hampton S, Bellamy J, Brown L, Doran E, Manzanares E, Palmer J,
22 Sanders A, Bokhari F, Fenuyi O, Greer C, Jang H, Juanillo A, Reese C, Narla D, Okoko I,
23 Woodham C, Eaton R, Khawaja S, Mushtag T, Bhutto AN, Solorsano S, Ahmed S,
24 Shamim R, Gonzalez N, Ardoin F, Moore J, Nuncio N, Ray E, Sikes K, Troutman I, West

1 N, Wilson Q, Young N, Baloch M, Karimjee N, Carroll K, Broachwala S, Calais N, Laabs
2 J, Marler K, Rizvi S, Syed A, Syed N, Rizvi Z, Hariwala Z, Gloyd P, Rizvi A, Marcum B,
3 Carswell J, Fanning C, Bull L, Corta P, James H, Martinez D, Scurlark R, Elliott S, Beck
4 S, Beck C, Glover S, Bonson J, Patel T, Matthew G, Davidoff K, Vesely J, Horton C,
5 Barbour R, Pereira I, Rivero G, Alston D, Miller P, Downing F, Crespo NS, Schwartz H,
6 Mederos S, Tamayo JS, Shapiro C, Mallet O, Plotka K, Valladares C, Palmer K, Deltejo
7 D, Garcia K, Camacho M, Chanza Y, Morera J, Davis C, Dawson K, Rosales V, Torres D,
8 Pinero M, Cruz C, Rivera B, Balebona P, Basurco A, Montoya J, Yaniz M, Phar PP,
9 Filgueiras C, Fernandez M, Skrine L, Alcantara A, Parodis I, Parodis J, Jara J, Alouption
10 J, Yan M, Padilla J, Cruz C, Bran B, Flores V, Perez L, Labovitz A, Roth T, Javier J,
11 Jimenez L, Ojeda C, Caceres M, Misir C, Rudd K, Ramos J, Deeb W, Bisharat M,
12 Dennis-Saltz A, Sutton D, Magee J, Ashchi M, Goldfaden R, Sheikh-Ali M, Kelly S,
13 Saikali EN, Ramirez GR, Domingo D, Hodge W, Greenewalt A, Stamschror L, Preston
14 K, Petschonek L, Graf K, Sutton L, Edson M, Charron M, Taylor M, Knisely E, Gore A,
15 Jones T, Johns B, Sheldon J, Merritt K, Hichkad L, Barbee L, Riley A, Alexander L,
16 Dasher L, Lopez EAT, Bonilla RB, Loza A, Hernandez D, Perez Y, Perez A, Perez Y,
17 Medina D, Mantero E, Vega R, Pedraza N, Sosa D, Robles L, Machado Y, Sosa Y,
18 Guzman D, Grio M, Frias J, Kelly S, Leibowitz M, Nelson J, Handy C, Greenberg A,
19 Vega N, Francisco A, Soto C, Arcadia S, Francisco E, Escareno N, Ayala N, Muniz J,
20 Espino J, Vargas D, Jimenez R, Lopez S, Gallaga I, Heredia G, Santana EB, Mendoza-
21 Rodriguez R, Santana SC, Román A, Torres IA, Franceschini V, Garcia B, Jimenez N,
22 Ortiz MI, Antommattei AT, Comulada-Rivera A, Pintado A, Ortiz S, Rodriguez A,
23 Ramirez RM, Olofintuyi A, Alvarez R, Pitts J, Samraj J, Vasbinder A, Averett A, Kane T,
24 Farley H, Kendall T, Kemmerlin R, Saunders J, Livingston Y, McLean B, Mayer M,

1 Goodwin V, Ngugi E, Mishra P, Carter H, Szymela L, Imran A, Abdallah S, Clarke N,
2 Latog SH, Moore B, Lopez M, Tagsip M, Nepali P, Kumaran N, Jacinto G, Magsino C,
3 Batalla F, Imran F, Montgomery R, Riggs S, Haamid S, Whitt C, Hopper W, Smith D,
4 Kordsmeier J, Sherron C, Plummer M, Jimenez S, Newkirk A, Murray L, Scott H,
5 Whitney R, Castro M, Rhames M, Cortes-Maisonet G, Martinez LM, Allende-Vigo M,
6 Vila K, Rivera MS, Yunker V, Rivera B, Rodriguez A, Rivera C, Blanco GR, Colon KB,
7 Cruz M, Nweke C, Okafor N, Nweke A, Chaves-Montoya D, Patrick H, Alvarez S,
8 Momeh E, Anaele C, McArthur K, Longonje P, Husbands D, Williams I, Dillingham C,
9 Sayyah GS, Carey L, Brock C, Hussain R, Sultana K, Mohammad O, Lopez J,
10 Bittencourt V, Prasad S, Akther N, Smith T, Rocco S, Straatmann D, Stoneman J,
11 Maryas E, Gravier J, Faggett W, Jimenez A, Alvarez MM, Evora W, Herrera A,
12 Leonardi L, Karns A, Sisneros E, Hong S, Rudyk I, Medentseva O, Alexeeva M,
13 Strakhova N, Lozyk T, Babichev D, Yushko K, Tseluyko V, Zhadan A, Butko O,
14 Mishchenko O, Radchenko O, Karpenko O, Klimko P, Berezhniak A, Todorik L,
15 Bezuglova S, Mitskevych L, Kizim S, Nevolina I, Galchenko O, Korzh O, Pankova O,
16 Fylenko Y, Ziabchenko V, Krasnokutskiy S, Liashok A, Donets O, Mishustina A,
17 Khrustalyova L, Donets D, Rybachok Y, Senchylo V, Lyakhova I, Takhaieva O, Shkroba
18 A, Shchypak D, Tryshchuk N, Pieshkova O, Karaia O, Yakovleva A, Horoshko O,
19 Lohdanidi T, Belei N, Kuzmenko I, Demchuk T, Cherniuk S, Kozliuk A, Kovalenko V,
20 Adarichev V, Vakaliuk I, Tymochko N, Sovtus V, Haliuk N, Gaudet D, Côté F, Milot J-P,
21 Roy N, Larouche A, Piché J, Charest L-A, Dufour J, Pageau J, Audet-Verreault N, Côté
22 L, Gagnon M, Côté V, Morin D, Fortin-Mimeault J, Brassard M-O, Gagne H, Rousseau
23 S, Sia YT, Guzzetti E, Gisbert RA, Dias M, Oliveira M de, Cote C, Rodrigues I, Blanchard
24 J, Labbe L, Lemay SD, Beauchemin K, Turcotte R, Beaudoin A, Saliphod C,

1 Lamontagne C, Trudel J, Beaudoin C, Blanchard J, Larouche A, Robinaud C, Paré V,
2 Bergeron A, Bilodeau M, Bellavance E, Betit E, Fortier K, Racine J, Perras D, Boulanger
3 E, Beauchesne C, Lehoux S, Turgeon V, Cote R, Tardif M-E, Aggarwal N, Aggarwal P,
4 Patel B, Dhaliwal G, Aggarwal P, Tellier G, Gagne G, Laperriere L, Shalala J, Danchuk J,
5 Barrette C, Lauzon L, Langille N, Gagné S, Lupien J, Brochu R, Coallier S, Vaillancourt
6 C, Lachance P, Carbonneau D, Thibault H, Bouchard L, St-Cyr A, Rioux J, Quenneville
7 L, Gagnon C, Nony T, Laberge P, Corbin A, Patry I, Savage S, MacNeil M, Murdock A,
8 Inglis J, Libbus K, Smith K, Johnson D, Walters-Findlay L, Harris L, Hutchison T, Rafuse
9 A, Thorsen J, MacDonald G, Akhras R, Assef R, Irani E, Khayat R, Guidolin S, Gupta A,
10 Price D, Gandhi A, Chhabra A, Gandhi B, Acharya S, Panchal M, Kansal B, Bailey G,
11 Harvalik P, Demchuk K, Saxena M, Collier D, David C, Quiros BJ, Patel M, Balawon A,
12 Galera F, Michalska A, Piniera B, Uddin R, Abbott J, Faulkner K, Yousef T, Love K,
13 Zagdanski A, Slaney S, Anderson M, Leath A, Dunlop C, Hardy E, Wall S, El-Koubani O,
14 Kelt T, Connolly B-J, Marmion C, Alapati M, Simmons L, Colquhoun C, Clyde D, Mooty
15 A, Mullen N, Viljoen M, Trevor L, Pretswell C, Austin C, Munthali C, Munsoor I,
16 Gowda MV, Ozunlu P, Keighley P, Jones A, James A, Pollitt J, Littlewood W, Al-
17 Sheikhly L, Lee D, Nistor D, Roberts E, Mawdsley G, Sobolewska K, Hannis K,
18 Wojtkiewicz K, Stopford L, Halliwell L, Mort V, McGrath V, Osborne H, Merrick A,
19 Basikolo C, Ghysels I, Fenlon L, Beech L, Munoz OL, Bilton S, Goddard L, Gillon T,
20 Taylor S, Tyson B, Connor V, Felber H, Fallows A, Clowes J and Cheung S (2024) RNA
21 Interference With Zilebesiran for Mild to Moderate Hypertension: The KARDIA-1
22 Randomized Clinical Trial. *JAMA* 331(9), 740–749.
23 <https://doi.org/10.1001/jama.2024.0728>.

- 1 Brown MJ (2012) Platt versus Pickering: what molecular insight to primary
2 hyperaldosteronism tells us about hypertension. *JRSM Cardiovascular Disease* 1(6),
3 cvd.2012.012020. <https://doi.org/10.1258/cvd.2012.012020>.
- 4 Burgess S, Butterworth A, Malarstig A and Thompson SG (2012) Use of Mendelian
5 randomisation to assess potential benefit of clinical intervention. *BMJ* 345.
6 <https://doi.org/10.1136/bmj.e7325>.
- 7 Bycroft C, Freeman C, Petkova D, Band G, Elliott LT, Sharp K, Motyer A, Vukcevic D, Delaneau
8 O, O'Connell J, Cortes A, Welsh S, Young A, Effingham M, McVean G, Leslie S, Allen N,
9 Donnelly P and Marchini J (2018) The UK Biobank resource with deep phenotyping
10 and genomic data. *Nature* 562(7726), 203–209. [https://doi.org/10.1038/s41586-](https://doi.org/10.1038/s41586-018-0579-z)
11 [018-0579-z](https://doi.org/10.1038/s41586-018-0579-z).
- 12 Caulfield M, Munroe P, Pembroke J, Samani N, Dominiczak A, Brown M, Webster J, Ratcliffe
13 P, O'Shea S, Papp J, Taylor E, Dobson R, Knight J, Newhouse S, Hooper J, Lee W, Brain
14 N, Clayton D, Lathrop GM, Farrall M, Connell J and Benjamin N (2003) Genome-wide
15 mapping of human loci for essential hypertension. *The Lancet* 361(9375), 2118–
16 2123. [https://doi.org/10.1016/S0140-6736\(03\)13722-1](https://doi.org/10.1016/S0140-6736(03)13722-1).
- 17 Cheng X, Waghulde H, Mell B, Morgan EE, Pruett-Miller SM and Joe B (2017) Positional
18 cloning of quantitative trait nucleotides for blood pressure and cardiac QT-interval
19 by targeted CRISPR/Cas9 editing of a novel long non-coding RNA. *PLOS Genetics*
20 13(8), e1006961. <https://doi.org/10.1371/journal.pgen.1006961>.
- 21 Cho YS, Go MJ, Kim YJ, Heo JY, Oh JH, Ban H-J, Yoon D, Lee MH, Kim D-J, Park M, Cha S-H,
22 Kim J-W, Han B-G, Min H, Ahn Y, Park MS, Han HR, Jang H-Y, Cho EY, Lee J-E, Cho NH,
23 Shin C, Park T, Park JW, Lee J-K, Cardon L, Clarke G, McCarthy MI, Lee J-Y, Lee J-K, Oh
24 B and Kim H-L (2009) A large-scale genome-wide association study of Asian

- 1 populations uncovers genetic factors influencing eight quantitative traits. *Nature*
2 *Genetics* 41(5), 527–534. <https://doi.org/10.1038/ng.357>.
- 3 Clarke R, Wright N, Walters R, Gan W, Guo Y, Millwood IY, Yang L, Chen Y, Lewington S, Lv J,
4 Yu C, Avery D, Lin K, Wang K, Peto R, Collins R, Li L, Bennett DA, Parish S, Chen Z and
5 Group† on behalf of the CKBC (2023) Genetically Predicted Differences in Systolic
6 Blood Pressure and Risk of Cardiovascular and Noncardiovascular Diseases: A
7 Mendelian Randomization Study in Chinese Adults. *Hypertension*.
8 <https://doi.org/10.1161/HYPERTENSIONAHA.122.20120>.
- 9 Cotto KC, Wagner AH, Feng Y-Y, Kiwala S, Coffman AC, Spies G, Wollam A, Spies NC, Griffith
10 OL and Griffith M (2018) DGIdb 3.0: a redesign and expansion of the drug–gene
11 interaction database. *Nucleic Acids Research* 46(D1), D1068–D1073.
12 <https://doi.org/10.1093/nar/gkx1143>.
- 13 Cowley AW (2006) The genetic dissection of essential hypertension. *Nature Reviews*
14 *Genetics* 7(11), 829–840. <https://doi.org/10.1038/nrg1967>.
- 15 Desai AS, Webb DJ, Taubel J, Casey S, Cheng Y, Robbie GJ, Foster D, Huang SA, Rhyee S,
16 Sweetser MT and Bakris GL (2023) Zilebesiran, an RNA Interference Therapeutic
17 Agent for Hypertension. *New England Journal of Medicine*.
18 <https://doi.org/10.1056/NEJMoa2208391>.
- 19 Ding Y, Hou K, Burch KS, Lapinska S, Privé F, Vilhjálmsson B, Sankararaman S and Pasaniuc B
20 (2021) Large uncertainty in individual polygenic risk score estimation impacts PRS-
21 based risk stratification. *Nature Genetics* 54(1), 30. <https://doi.org/10.1038/s41588-021-00961-5>.
- 22
23 Duijvenboden S van, Ramírez J, Young WJ, Olczak KJ, Ahmed F, Alhammad MJAY, Bell CG,
24 Morris AP and Munroe PB (2023) Integration of genetic fine-mapping and multi-

- 1 omics data reveals candidate effector genes for hypertension. *The American Journal*
2 *of Human Genetics* 110(10), 1718–1734. <https://doi.org/10.1016/j.ajhg.2023.08.009>.
- 3 Dzau VJ and Hodgkinson CP (2024) Precision Hypertension. *Hypertension*.
4 <https://doi.org/10.1161/HYPERTENSIONAHA.123.21710>.
- 5 Eales JM, Jiang X, Xu X, Saluja S, Akbarov A, Cano-Gamez E, McNulty MT, Finan C, Guo H,
6 Wystrychowski W, Szulinska M, Thomas HB, Pramanik S, Chopade S, Prestes PR, Wise
7 I, Evangelou E, Salehi M, Shakanti Y, Ekholm M, Denniff M, Nazgiewicz A, Eichinger F,
8 Godfrey B, Antczak A, Glyda M, Król R, Eyre S, Brown J, Berzuini C, Bowes J, Caulfield
9 M, Zukowska-Szczechowska E, Zywiec J, Bogdanski P, Kretzler M, Woolf AS, Talavera
10 D, Keavney B, Maffia P, Guzik TJ, O’Keefe RT, Trynka G, Samani NJ, Hingorani A,
11 Sampson MG, Morris AP, Charchar FJ and Tomaszewski M (2021) Uncovering genetic
12 mechanisms of hypertension through multi-omic analysis of the kidney. *Nature*
13 *Genetics* 53(5), 630–637. <https://doi.org/10.1038/s41588-021-00835-w>.
- 14 Ehret GB, Morrison AC, O’Connor AA, Grove ML, Baird L, Schwander K, Weder A, Cooper RS,
15 Rao DC, Hunt SC, Boerwinkle E and Chakravarti A (2008) Replication of the Wellcome
16 Trust genome-wide association study of essential hypertension: the Family Blood
17 Pressure Program. *European Journal of Human Genetics* 16(12), 1507–1511.
18 <https://doi.org/10.1038/ejhg.2008.102>.
- 19 Ehret GB, Munroe PB, Rice KM, Bochud M, Johnson AD, Chasman DI, Smith AV, Tobin MD,
20 Verwoert GC, Hwang S-J, Pihur V, Vollenweider P, O’Reilly PF, Amin N, Bragg-
21 Gresham JL, Teumer A, Glazer NL, Launer L, Hua Zhao J, Aulchenko Y, Heath S, Söber
22 S, Parsa A, Luan J, Arora P, Dehghan A, Zhang F, Lucas G, Hicks AA, Jackson AU,
23 Peden JF, Tanaka T, Wild SH, Rudan I, Igl W, Milaneschi Y, Parker AN, Fava C,
24 Chambers JC, Fox ER, Kumari M, Jin Go M, van der Harst P, Hong Linda Kao W,

1 Sjögren M, Vinay DG, Alexander M, Tabara Y, Shaw-Hawkins S, Whincup PH, Liu Y,
2 Shi G, Kuusisto J, Tayo B, Seielstad M, Sim X, Hoang Nguyen K-D, Lehtimäki T, Matullo
3 G, Wu Y, Gaunt TR, Charlotte Onland-Moret N, Cooper MN, Platou CGP, Org E, Hardy
4 R, Dahgam S, Palmen J, Vitart V, Braund PS, Kuznetsova T, Uiterwaal CSPM, Adeyemo
5 A, Palmas W, Campbell H, Ludwig B, Tomaszewski M, Tzoulaki I, Palmer ND,
6 Aspelund T, Garcia M, Chang Y-PC, O'Connell JR, Steinle NI, Grobbee DE, Arking DE,
7 Kardia SL, Morrison AC, Hernandez D, Najjar S, McArdle WL, Hadley D, Brown MJ,
8 Connell JM, Hingorani AD, Day INM, Lawlor DA, Beilby JP, Lawrence RW, Clarke R,
9 Hopewell JC, Ongen H, Dreisbach AW, Li Y, Hunter Young J, Bis JC, Kähönen M, Viikari
10 J, Adair LS, Lee NR, Chen M-H, Olden M, Pattaro C, Hoffman Bolton JA, Köttgen A,
11 Bergmann S, Mooser V, Chaturvedi N, Frayling TM, Islam M, Jafar TH, Erdmann J,
12 Kulkarni SR, Bornstein SR, Grässler J, Groop L, Voight BF, Kettunen J, Howard P,
13 Taylor A, Guarrera S, Ricceri F, Emilsson V, Plump A, Barroso I, Khaw K-T, Weder AB,
14 Hunt SC, Sun YV, Bergman RN, Collins FS, Bonnycastle LL, Scott LJ, Stringham HM,
15 Peltonen L, Perola M, Vartiainen E, Brand S-M, Staessen JA, Wang TJ, Burton PR,
16 Soler Artigas M, Dong Y, Snieder H, Wang X, Zhu H, Lohman KK, Rudock ME,
17 Heckbert SR, Smith NL, Wiggins KL, Doumatey A, Shriner D, Veldre G, Viigimaa M,
18 Kinra S, Prabhakaran D, Tripathy V, Langefeld CD, Rosengren A, Thelle DS, Maria
19 Corsi A, Singleton A, Forrester T, Hilton G, McKenzie CA, Salako T, Iwai N, Kita Y,
20 Ogiwara T, Ohkubo T, Okamura T, Ueshima H, Umemura S, Eyheramendy S,
21 Meitinger T, Wichmann H-E, Shin Cho Y, Kim H-L, Lee J-Y, Scott J, Sehmi JS, Zhang W,
22 Hedblad B, Nilsson P, Davey Smith G, Wong A, Narisu N, Stančáková A, Raffel LJ, Yao
23 J, Kathiresan S, O'Donnell CJ, Schwartz SM, Arfan Ikram M, Longstreth Jr WT, Mosley
24 TH, Seshadri S, Shrine NRG, Wain LV, Morken MA, Swift AJ, Laitinen J, Prokopenko I,

1 Zitting P, Cooper JA, Humphries SE, Danesh J, Rasheed A, Goel A, Hamsten A,
2 Watkins H, Bakker SJL, van Gilst WH, Janipalli CS, Radha Mani K, Yajnik CS, Hofman A,
3 Mattace-Raso FUS, Oostra BA, Demirkan A, Isaacs A, Rivadeneira F, Lakatta EG, Orru
4 M, Scuteri A, Ala-Korpela M, Kangas AJ, Lyytikäinen L-P, Soininen P, Tukiainen T,
5 Würtz P, Tzee-Hee Ong R, Dörr M, Kroemer HK, Völker U, Völzke H, Galan P,
6 Hercberg S, Lathrop M, Zelenika D, Deloukas P, Mangino M, Spector TD, Zhai G,
7 Meschia JF, Nalls MA, Sharma P, Terzic J, Kranthi Kumar MV, Denniff M, Zukowska-
8 Szczechowska E, Wagenknecht LE, Gerald R. Fowkes F, Charchar FJ, Schwarz PEH,
9 Hayward C, Guo X, Rotimi C, Bots ML, Brand E, Samani NJ, Polasek O, Talmud PJ,
10 Nyberg F, Kuh D, Laan M, Hveem K, Palmer LJ, van der Schouw YT, Casas JP, Mohlke
11 KL, Vineis P, Raitakari O, Ganesh SK, Wong TY, Shyong Tai E, Cooper RS, Laakso M,
12 Rao DC, Harris TB, Morris RW, Dominiczak AF, Kivimaki M, The International
13 Consortium for Blood Pressure Genome-Wide Association Studies, CARDIoGRAM
14 consortium, CKDGen Consortium, KidneyGen Consortium, EchoGen consortium, and
15 CHARGE-HF consortium (2011) Genetic variants in novel pathways influence blood
16 pressure and cardiovascular disease risk. *Nature* 478(7367), 103–109.

17 <https://doi.org/10.1038/nature10405>.

18 Genome Research Biobank Project Biobank Japan (BBJ)

19 <https://biobankjp.org/english/index.html>

20 Evangelou E, Warren HR, Mosen-Ansorena D, Mifsud B, Pazoki R, Gao H, Ntritsos G, Dimou
21 N, Cabrera CP, Karaman I, Ng FL, Evangelou M, Witkowska K, Tzani E, Hellwege JN,
22 Giri A, Velez Edwards DR, Sun YV, Cho K, Gaziano JM, Wilson PWF, Tsao PS, Kovesdy
23 CP, Esko T, Mägi R, Milani L, Almgren P, Boutin T, Debette S, Ding J, Giulianini F,
24 Holliday EG, Jackson AU, Li-Gao R, Lin W-Y, Luan J, Mangino M, Oldmeadow C, Prins

1 BP, Qian Y, Sargurupremraj M, Shah N, Surendran P, Thériault S, Verweij N, Willems
2 SM, Zhao J-H, Amouyel P, Connell J, de Mutsert R, Doney ASF, Farrall M, Menni C,
3 Morris AD, Noordam R, Paré G, Poulter NR, Shields DC, Stanton A, Thom S, Abecasis
4 G, Amin N, Arking DE, Ayers KL, Barbieri CM, Batini C, Bis JC, Blake T, Bochud M,
5 Boehnke M, Boerwinkle E, Boomsma DI, Bottinger EP, Braund PS, Brumat M,
6 Campbell A, Campbell H, Chakravarti A, Chambers JC, Chauhan G, Ciullo M, Cocca M,
7 Collins F, Cordell HJ, Davies G, de Borst MH, de Geus EJ, Deary IJ, Deelen J, Del Greco
8 M. F, Demirkale CY, Dörr M, Ehret GB, Elosua R, Enroth S, Erzurumluoglu AM,
9 Ferreira T, Frånberg M, Franco OH, Gandin I, Gasparini P, Giedraitis V, Gieger C,
10 Girotto G, Goel A, Gow AJ, Gudnason V, Guo X, Gyllensten U, Hamsten A, Harris TB,
11 Harris SE, Hartman CA, Havulinna AS, Hicks AA, Hofer E, Hofman A, Hottenga J-J,
12 Huffman JE, Hwang S-J, Ingelsson E, James A, Jansen R, Jarvelin M-R, Joehanes R,
13 Johansson Å, Johnson AD, Joshi PK, Jousilahti P, Jukema JW, Jula A, Kähönen M,
14 Kathiresan S, Keavney BD, Khaw K-T, Knekt P, Knight J, Kolcic I, Kooner JS, Koskinen S,
15 Kristiansson K, Kutalik Z, Laan M, Larson M, Launer LJ, Lehne B, Lehtimäki T, Liewald
16 DCM, Lin L, Lind L, Lindgren CM, Liu Y, Loos RJF, Lopez LM, Lu Y, Lyytikäinen L-P,
17 Mahajan A, Mamasoula C, Marrugat J, Marten J, Milaneschi Y, Morgan A, Morris AP,
18 Morrison AC, Munson PJ, Nalls MA, Nandakumar P, Nelson CP, Niiranen T, Nolte IM,
19 Nutile T, Oldehinkel AJ, Oostra BA, O'Reilly PF, Org E, Padmanabhan S, Palmas W,
20 Palotie A, Pattie A, Penninx BWJH, Perola M, Peters A, Polasek O, Pramstaller PP,
21 Nguyen QT, Raitakari OT, Ren M, Rettig R, Rice K, Ridker PM, Ried JS, Riese H, Ripatti
22 S, Robino A, Rose LM, Rotter JI, Rudan I, Ruggiero D, Saba Y, Sala CF, Salomaa V,
23 Samani NJ, Sarin A-P, Schmidt R, Schmidt H, Shrine N, Siscovick D, Smith AV, Snieder
24 H, Söber S, Sorice R, Starr JM, Stott DJ, Strachan DP, Strawbridge RJ, Sundström J,

1 Swertz MA, Taylor KD, Teumer A, Tobin MD, Tomaszewski M, Toniolo D, Traglia M,
2 Trompet S, Tuomilehto J, Tzourio C, Uitterlinden AG, Vaez A, van der Most PJ, van
3 Duijn CM, Vergnaud A-C, Verwoert GC, Vitart V, Völker U, Vollenweider P, Vuckovic
4 D, Watkins H, Wild SH, Willemsen G, Wilson JF, Wright AF, Yao J, Zemunik T, Zhang
5 W, Attia JR, Butterworth AS, Chasman DI, Conen D, Cucca F, Danesh J, Hayward C,
6 Howson JMM, Laakso M, Lakatta EG, Langenberg C, Melander O, Mook-Kanamori
7 DO, Palmer CNA, Risch L, Scott RA, Scott RJ, Sever P, Spector TD, van der Harst P,
8 Wareham NJ, Zeggini E, Levy D, Munroe PB, Newton-Cheh C, Brown MJ, Metspalu A,
9 Hung AM, O'Donnell CJ, Edwards TL, Psaty BM, Tzoulaki I, Barnes MR, Wain LV,
10 Elliott P and Caulfield MJ (2018) Genetic analysis of over 1 million people identifies
11 535 new loci associated with blood pressure traits. *Nature Genetics* 50(10), 1412–
12 1425. <https://doi.org/10.1038/s41588-018-0205-x>.

13 Feitosa MF, Kraja AT, Chasman DI, Sung YJ, Winkler TW, Ntalla I, Guo X, Franceschini N,
14 Cheng C-Y, Sim X, Vojinovic D, Marten J, Musani SK, Li C, Bentley AR, Brown MR,
15 Schwander K, Richard MA, Noordam R, Aschard H, Bartz TM, Bielak LF, Dorajoo R,
16 Fisher V, Hartwig FP, Horimoto ARVR, Lohman KK, Manning AK, Rankinen T, Smith
17 AV, Tajuddin SM, Wojczynski MK, Alver M, Boissel M, Cai Q, Campbell A, Chai JF,
18 Chen X, Divers J, Gao C, Goel A, Hagemeijer Y, Harris SE, He M, Hsu F-C, Jackson AU,
19 Kähönen M, Kasturiratne A, Komulainen P, Kühnel B, Laguzzi F, Luan J, Matoba N,
20 Nolte IM, Padmanabhan S, Riaz M, Rueedi R, Robino A, Said MA, Scott RA, Sofer T,
21 Stančáková A, Takeuchi F, Tayo BO, Most PJ van der, Varga TV, Vitart V, Wang Y,
22 Ware EB, Warren HR, Weiss S, Wen W, Yanek LR, Zhang W, Zhao JH, Afaq S, Amin N,
23 Amini M, Arking DE, Aung T, Boerwinkle E, Borecki I, Broeckel U, Brown M, Brumat
24 M, Burke GL, Canouil M, Chakravarti A, Charumathi S, Chen Y-DI, Connell JM, Correa

1 A, Fuentes L de las, Mutsert R de, Silva HJ de, Deng X, Ding J, Duan Q, Eaton CB, Ehret
2 G, Eppinga RN, Evangelou E, Faul JD, Felix SB, Forouhi NG, Forrester T, Franco OH,
3 Friedlander Y, Gandin I, Gao H, Ghanbari M, Gigante B, Gu CC, Gu D, Hagenaars SP,
4 Hallmans G, Harris TB, He J, Heikkinen S, Heng C-K, Hirata M, Howard BV, Ikram MA,
5 Consortium I, John U, Katsuya T, Khor CC, Kilpeläinen TO, Koh W-P, Krieger JE,
6 Kritchevsky SB, Kubo M, Kuusisto J, Lakka TA, Langefeld CD, Langenberg C, Launer LJ,
7 Lehne B, Lewis CE, Li Y, Lin S, Liu J, Liu J, Loh M, Louie T, Mägi R, McKenzie CA,
8 Meitinger T, Metspalu A, Milaneschi Y, Milani L, Mohlke KL, Momozawa Y, Nalls MA,
9 Nelson CP, Sotoodehnia N, Norris JM, O'Connell JR, Palmer ND, Perls T, Pedersen NL,
10 Peters A, Peyser PA, Poulter N, Raffel LJ, Raitakari OT, Roll K, Rose LM, Rosendaal FR,
11 Rotter JI, Schmidt CO, Schreiner PJ, Schupf N, Scott WR, Sever PS, Shi Y, Sidney S,
12 Sims M, Sitlani CM, Smith JA, Snieder H, Starr JM, Strauch K, Stringham HM, Tan
13 NYQ, Tang H, Taylor KD, Teo YY, Tham YC, Turner ST, Uitterlinden AG, Vollenweider
14 P, Waldenberger M, Wang L, Wang YX, Wei WB, Williams C, Yao J, Yu C, Yuan J-M,
15 Zhao W, Zonderman AB, Becker DM, Boehnke M, Bowden DW, Chambers JC, Deary
16 IJ, Esko T, Farrall M, Franks PW, Freedman BI, Froguel P, Gasparini P, Gieger C, Jonas
17 JB, Kamatani Y, Kato N, Kooner JS, Kutalik Z, Laakso M, Laurie CC, Leander K,
18 Lehtimäki T, Study LC, Magnusson PKE, Oldehinkel AJ, Penninx BWJH, Polasek O,
19 Porteous DJ, Rauramaa R, Samani NJ, Scott J, Shu X-O, Harst P van der, Wagenknecht
20 LE, Wareham NJ, Watkins H, Weir DR, Wickremasinghe AR, Wu T, Zheng W,
21 Bouchard C, Christensen K, Evans MK, Gudnason V, Horta BL, Kardina SLR, Liu Y,
22 Pereira AC, Psaty BM, Ridker PM, Dam RM van, Gauderman WJ, Zhu X, Mook-
23 Kanamori DO, Fornage M, Rotimi CN, Cupples LA, Kelly TN, Fox ER, Hayward C, Duijn
24 CM van, Tai ES, Wong TY, Kooperberg C, Palmas W, Rice K, Morrison AC, Elliott P,

1 Caulfield MJ, Munroe PB, Rao DC, Province MA and Levy D (2018) Novel genetic
2 associations for blood pressure identified via gene-alcohol interaction in up to 570K
3 individuals across multiple ancestries. *PLOS ONE* 13(6), e0198166.
4 <https://doi.org/10.1371/journal.pone.0198166>.

5 Franceschini N, Fox E, Zhang Z, Edwards TL, Nalls MA, Sung YJ, Tayo BO, Sun YV, Gottesman
6 O, Adeyemo A, Johnson AD, Young JH, Rice K, Duan Q, Chen F, Li Y, Tang H, Fornage
7 M, Keene KL, Andrews JS, Smith JA, Faul JD, Guangfa Z, Guo W, Liu Y, Murray SS,
8 Musani SK, Srinivasan S, Velez Edwards DR, Wang H, Becker LC, Bovet P, Bochud M,
9 Broeckel U, Burnier M, Carty C, Chasman DI, Ehret G, Chen W-M, Chen G, Chen W,
10 Ding J, Dreisbach AW, Evans MK, Guo X, Garcia ME, Jensen R, Keller MF, Lettre G,
11 Lotay V, Martin LW, Moore JH, Morrison AC, Mosley TH, Ogunniyi A, Palmas W,
12 Papanicolaou G, Penman A, Polak JF, Ridker PM, Salako B, Singleton AB, Shriner D,
13 Taylor KD, Vasan R, Wiggins K, Williams SM, Yanek LR, Zhao W, Zonderman AB,
14 Becker DM, Berenson G, Boerwinkle E, Bottinger E, Cushman M, Eaton C, Nyberg F,
15 Heiss G, Hirschhorn JN, Howard VJ, Karczewsk KJ, Lanktree MB, Liu K, Liu Y, Loos R,
16 Margolis K, Snyder M, Go MJ, Kim YJ, Lee J-Y, Jeon J-P, Kim SS, Han B-G, Cho YS, Sim
17 X, Tay WT, Ong RTH, Seielstad M, Liu JJ, Aung T, Wong TY, Teo YY, Tai ES, Chen C-H,
18 Chang L, Chen Y-T, Wu J-Y, Kelly TN, Gu D, Hixson JE, Sung YJ, He J, Tabara Y, Kokubo
19 Y, Miki T, Iwai N, Kato N, Takeuchi F, Katsuya T, Nabika T, Sugiyama T, Zhang Y,
20 Huang W, Zhang X, Zhou X, Jin L, Zhu D, Psaty BM, Schork NJ, Weir DR, Rotimi CN,
21 Sale MM, Harris T, Kardina SLR, Hunt SC, Arnett D, Redline S, Cooper RS, Risch NJ, Rao
22 DC, Rotter JI, Chakravarti A, Reiner AP, Levy D, Keating BJ and Zhu X (2013) Genome-
23 wide Association Analysis of Blood-Pressure Traits in African-Ancestry Individuals
24 Reveals Common Associated Genes in African and Non-African Populations. *The*

- 1 *American Journal of Human Genetics* 93(3), 545–554.
- 2 <https://doi.org/10.1016/j.ajhg.2013.07.010>.
- 3 Freeman MW, Halvorsen Y-D, Marshall W, Pater M, Isaacsohn J, Pearce C, Murphy B, Alp N,
4 Srivastava A, Bhatt DL and Brown MJ (2022) Phase 2 Trial of Baxdrostat for
5 Treatment-Resistant Hypertension. *New England Journal of Medicine*.
6 <https://doi.org/10.1056/NEJMoa2213169>.
- 7 Fuat A, Adlen E, Monane M, Coll R, Groves S, Little E, Wild J, Kamali FJ, Soni Y, Haining S,
8 Riding H, Riveros-Mckay F, Peneva I, Lachapelle A, Giner-Delgado C, Weale ME,
9 Plagnol V, Harrison S and Donnelly P (2024) A polygenic risk score added to a
10 QRISK®2 cardiovascular disease risk calculator demonstrated robust clinical
11 acceptance and clinical utility in the primary care setting. *European Journal of*
12 *Preventive Cardiology* 31(6), 716–722. <https://doi.org/10.1093/eurjpc/zwae004>.
- 13 Fujii R, Hishida A, Nakatochi M, Okumiyama H, Takashima N, Tsuboi Y, Suzuki K, Ikezaki H,
14 Shimano C, Kato Y, Tamura T, Ito H, Michihata N, Tanoue S, Suzuki S, Kuriki K,
15 Kadota A, Watanabe T, Momozawa Y, Wakai K and Matsuo K (2024) Polygenic risk
16 score for blood pressure and lifestyle factors with overall and CVD mortality: a
17 prospective cohort study in a Japanese population. *Hypertension Research* 47(9),
18 2284–2294. <https://doi.org/10.1038/s41440-024-01766-9>.
- 19 Ganji-Arjenaki M, Kamali Z, Evangelou E, Warren HR, Gao H, Ntritsos G, Dimou N, Esko T,
20 Mägi R, Milani L, Almgren P, Boutin T, Debette S, Ding J, Giulianini F, Holliday EG,
21 Jackson AU, Li -Gao R, Lin W-Y, Luan J, Mangino M, Oldmeadow C, Prins BP, Qian Y,
22 Sargurupremraj M, Shah N, Surendran P, Thériault S, Verweij N, Willems SM, Zhao J-
23 H, Amouyel P, Connell J, Mutsert R de, Doney ASF, Farrall M, Menni C, Morris AD,
24 Noordam R, Paré G, Poulter NR, Shields DC, Stanton A, Thom S, Abecasis G, Amin N,

1 Arking DE, Ayers KL, Barbieri CM, Batini C, Bis JC, Blake T, Bochud M, Boehnke M,
2 Boerwinkle E, Boomsma DI, Bottinger EP, Braund PS, Brumat M, Campbell A,
3 Campbell H, Chakravarti A, Chambers JC, Chauhan G, Ciullo M, Cocca M, Collins F,
4 Cordell HJ, Davies G, Borst MH de, Geus EJ de, Deary IJ, Deelen J, M FDG, Demirkale
5 CY, Dörr M, Ehret GB, Elosua R, Enroth S, Erzurumluoglu AM, Ferreira T, Frånberg M,
6 Franco OH, Gandin I, Gasparini P, Giedraitis V, Gieger C, Girotto G, Goel A, Gow AJ,
7 Gudnason V, Guo X, Gyllensten U, Hamsten A, Harris TB, Harris SE, Hartman CA,
8 Havulinna AS, Hicks AA, Hofer E, Hofman A, Hottenga J-J, Huffman JE, Hwang S-J,
9 Ingelsson E, James A, Jansen R, Jarvelin M-R, Joehanes R, Johansson Å, Johnson AD,
10 Joshi PK, Jousilahti P, Jukema JW, Jula A, Kähönen M, Kathiresan S, Keavney BD,
11 Khaw K-T, Knekt P, Knight J, Kolcic I, Kooner JS, Koskinen S, Kristiansson K, Kutalik Z,
12 Laan M, Larson M, Launer LJ, Lehne B, Lehtimäki T, Liewald DCM, Lin L, Lind L,
13 Lindgren CM, Liu Y, Loos RJF, Lopez LM, Lu Y, Lyytikäinen L-P, Mahajan A, Mamasoula
14 C, Marrugat J, Marten J, Milaneschi Y, Morgan A, Morris AP, Morrison AC, Munson
15 PJ, Nalls MA, Nandakumar P, Nelson CP, Niiranen T, Nolte IM, Nutile T, Oldehinkel AJ,
16 Oostra BA, O'Reilly PF, Org E, Padmanabhan S, Palmas W, Palotie A, Pattie A, Penninx
17 BWJH, Perola M, Peters A, Polasek O, Pramstaller PP, Nguyen QT, Raitakari OT, Rettig
18 R, Rice K, Ridker PM, Ried JS, Riese H, Ripatti S, Robino A, Rose LM, Rotter JI, Rudan I,
19 Ruggiero D, Saba Y, Sala CF, Salomaa V, Samani NJ, Sarin A-P, Schmidt R, Schmidt H,
20 Shrine N, Siscovick D, Smith AV, Snieder H, Söber S, Sorice R, Starr JM, Stott DJ,
21 Strachan DP, Strawbridge RJ, Sundström J, Swertz MA, Taylor KD, Teumer A, Tobin
22 MD, Tomaszewski M, Toniolo D, Traglia M, Trompet S, Tuomilehto J, Tzourio C,
23 Uitterlinden AG, Vaez A, Most PJ van der, Duijn CM van, Verwoert GC, Vitart V,
24 Völker U, Vollenweider P, Vuckovic D, Watkins H, Wild SH, Willemsen G, Wilson JF,

1 Wright AF, Yao J, Zemunik T, Zhang W, Attia JR, Butterworth AS, Chasman DI, Conen
2 D, Cucca F, Danesh J, Hayward C, Howson JMM, Laakso M, Lakatta EG, Langenberg C,
3 Melander O, Mook-Kanamori DO, Palmer CNA, Risch L, Scott RA, Scott RJ, Sever P,
4 Spector TD, Harst P van der, Wareham NJ, Zeggini E, Levy D, Munroe PB, Newton-
5 Cheh C, Brown MJ, Metspalu A, Psaty BM, Wain LV, Elliott P, Caulfield MJ, Sardari S,
6 Borst M de, Snieder H and Vaez A (2024) Prioritization of Kidney Cell Types Highlights
7 Myofibroblast Cells in Regulating Human Blood Pressure. *Kidney International*
8 *Reports* 9(6), 1849–1859. <https://doi.org/10.1016/j.ekir.2024.03.001>.

9 Gaulton A, Hersey A, Nowotka M, Bento AP, Chambers J, Mendez D, Mutowo P, Atkinson F,
10 Bellis LJ, Cibrián-Uhalte E, Davies M, Dedman N, Karlsson A, Magariños MP,
11 Overington JP, Papadatos G, Smit I and Leach AR (2017) The ChEMBL database in
12 2017. *Nucleic Acids Research* 45(D1), D945–D954.
13 <https://doi.org/10.1093/nar/gkw1074>.

14 Ge T, Chen C-Y, Ni Y, Feng Y-CA and Smoller JW (2019) Polygenic prediction via Bayesian
15 regression and continuous shrinkage priors. *Nature Communications* 10(1), 1–10.
16 <https://doi.org/10.1038/s41467-019-09718-5>.

17 GenomeAsia. <https://www.genomeasia100k.org/>

18 Genomics PLC - Genomics plc. <https://www.genomicsplc.com/>

19 Giri A, Hellwege JN, Keaton JM, Park J, Qiu C, Warren HR, Torstenson ES, Kovesdy CP, Sun
20 YV, Wilson OD, Robinson-Cohen C, Roumie CL, Chung CP, Birdwell KA, Damrauer SM,
21 DuVall SL, Klarin D, Cho K, Wang Y, Evangelou E, Cabrera CP, Wain LV, Shrestha R,
22 Mautz BS, Akwo EA, Sargurupremraj M, Debette S, Boehnke M, Scott LJ, Luan J, Jing-
23 Hua Z, Willems SM, Thériault S, Shah N, Oldmeadow C, Almgren P, Li-Gao R, Verweij
24 N, Boutin TS, Mangino M, Ntalla I, Feofanova E, Surendran P, Cook JP, Karthikeyan S,

1 Lahrouchi N, Liu C, Sepúlveda N, Richardson TG, Kraja A, Amouyel P, Farrall M,
2 Poulter NR, Group USS, Pressure IC for B, Studies BP-IC of E chip, Laakso M, Zeggini E,
3 Sever P, Scott RA, Langenberg C, Wareham NJ, Conen D, Palmer CNA, Attia J,
4 Chasman DI, Ridker PM, Melander O, Mook-Kanamori DO, Harst P van der, Cucca F,
5 Schlessinger D, Hayward C, Spector TD, Marjo-Riitta J, Hennig BJ, Timpson NJ, Wei-Qi
6 W, Smith JC, Xu Y, Matheny ME, Siew EE, Lindgren C, Karl-Heinz H, Dedoussis G,
7 Denny JC, Psaty BM, Howson JMM, Munroe PB, Newton-Cheh C, Caulfield MJ, Elliott
8 P, Gaziano JM, Concato J, Wilson PWF, Tsao PS, Edwards DRV, Susztak K, Program
9 MV, O'Donnell CJ, Hung AM and Edwards TL (2019) Trans-ethnic association study of
10 blood pressure determinants in over 750,000 individuals. *Nature Genetics* 51(1), 51.
11 <https://doi.org/10.1038/s41588-018-0303-9>.

12 Global burden of hypertension: analysis of worldwide data (2005) *The Lancet* 365(9455),
13 217–223. [https://doi.org/10.1016/S0140-6736\(05\)17741-1](https://doi.org/10.1016/S0140-6736(05)17741-1).

14 Guirette M, Lan J, McKeown NM, Brown MR, Chen H, Vries PS de, Kim H, Rebholz CM,
15 Morrison AC, Bartz TM, Fretts AM, Guo X, Lemaitre RN, Liu C-T, Noordam R, Mutsert
16 R de, Rosendaal FR, Wang CA, Beilin LJ, Mori TA, Oddy WH, Pennell CE, Chai JF,
17 Whitton C, Dam RM van, Liu J, Tai ES, Sim X, Neuhauser ML, Kooperberg C, Tinker LF,
18 Franceschini N, Huan T, Winkler TW, Bentley AR, Gauderman WJ, Heerkens L, Tanaka
19 T, Rooij J van, Munroe PB, Warren HR, Voortman T, Chen H, Rao DC, Levy D, Ma J
20 and Group O behalf of the CG-LIW (2024) Genome-Wide Interaction Analysis With
21 DASH Diet Score Identified Novel Loci for Systolic Blood Pressure. *Hypertension*.
22 <https://doi.org/10.1161/HYPERTENSIONAHA.123.22334>.

23 H3Africa – Human Heredity & Health in Africa. <https://h3africa.org/>

- 1 He KY, Kelly TN, Wang H, Liang J, Zhu L, Cade BE, Assimes TL, Becker LC, Beitelshes AL,
2 Bielak LF, Bress AP, Brody JA, Chang Y-PC, Chang Y-C, de Vries PS, Duggirala R, Fox
3 ER, Franceschini N, Furniss AL, Gao Y, Guo X, Haessler J, Hung Y-J, Hwang S-J, Irvin
4 MR, Kalyani RR, Liu C-T, Liu C, Martin LW, Montasser ME, Muntner PM, Mwasongwe
5 S, Naseri T, Palmas W, Reupena MS, Rice KM, Sheu WH-H, Shimbo D, Smith JA,
6 Snively BM, Yanek LR, Zhao W, Blangero J, Boerwinkle E, Chen Y-DI, Correa A,
7 Cupples LA, Curran JE, Fornage M, He J, Hou L, Kaplan RC, Kardia SLR, Kenny EE,
8 Kooperberg C, Lloyd-Jones D, Loos RJF, Mathias RA, McGarvey ST, Mitchell BD, North
9 KE, Peyser PA, Psaty BM, Raffield LM, Rao DC, Redline S, Reiner AP, Rich SS, Rotter JI,
10 Taylor KD, Tracy R, Vasan RS, Morrison AC, Levy D, Chakravarti A, Arnett DK and Zhu
11 X (2022) Rare coding variants in RCN3 are associated with blood pressure. *BMC*
12 *Genomics* 23(1), 1–18. <https://doi.org/10.1186/s12864-022-08356-4>.
- 13 Hoffmann TJ, Ehret GB, Nandakumar P, Ranatunga D, Schaefer C, Kwok P-Y, Iribarren C,
14 Chakravarti A and Risch N (2017) Genome-wide association analyses using electronic
15 health records identify new loci influencing blood pressure variation. *Nature*
16 *Genetics* 49(1), 54–64. <https://doi.org/10.1038/ng.3715>.
- 17 Qatar Biobank (n.d.). <https://www.qatarbiobank.org.qa/>
- 18 Hong K-W, Jin H-S, Cho YS, Lee J-Y, Lee J-E, Cho NH, Shin C, Lee S-H, Park HK and Oh B (2009)
19 Replication of the Wellcome Trust genome-wide association study on essential
20 hypertension in a Korean population. *Hypertension Research* 32(7), 570–574.
21 <https://doi.org/10.1038/hr.2009.68>.
- 22 International Human Genome Sequencing Consortium (2004) Finishing the euchromatic
23 sequence of the human genome. *Nature* 431(7011), 931–945.
24 <https://doi.org/10.1038/nature03001>.

- 1 Kamali Z, Keaton JM, Haghjooy Javanmard S, International Consortium of Blood Pressure,
2 Million Veteran Program, eQTLGen Consortium, BIOS Consortium, Edwards TL,
3 Snieder H and Vaez A (2022) Large-Scale Multi-Omics Studies Provide New Insights
4 into Blood Pressure Regulation. *International Journal of Molecular Sciences* 23(14),
5 7557. <https://doi.org/10.3390/ijms23147557>.
- 6 Kauko A, Aittokallio J, Vaura F, Ji H, Ebinger JE, Niiranen T and Cheng S (2021) Sex
7 Differences in Genetic Risk for Hypertension. *Hypertension*.
8 <https://doi.org/10.1161/HYPERTENSIONAHA.121.17796>.
- 9 Keaton JM, Kamali Z, Xie T, Vaez A, Williams A, Goleva SB, Ani A, Evangelou E, Hellwege JN,
10 Yengo L, Young WJ, Traylor M, Giri A, Zheng Z, Zeng J, Chasman DI, Morris AP,
11 Caulfield MJ, Hwang S-J, Kooner JS, Conen D, Attia JR, Morrison AC, Loos RJF,
12 Kristiansson K, Schmidt R, Hicks AA, Pramstaller PP, Nelson CP, Samani NJ, Risch L,
13 Gyllensten U, Melander O, Riese H, Wilson JF, Campbell H, Rich SS, Psaty BM, Lu Y,
14 Rotter JI, Guo X, Rice KM, Vollenweider P, Sundström J, Langenberg C, Tobin MD,
15 Giedraitis V, Luan J, Tuomilehto J, Kutalik Z, Ripatti S, Salomaa V, Girotto G, Trompet
16 S, Jukema JW, van der Harst P, Ridker PM, Giulianini F, Vitart V, Goel A, Watkins H,
17 Harris SE, Deary IJ, van der Most PJ, Oldehinkel AJ, Keavney BD, Hayward C,
18 Campbell A, Boehnke M, Scott LJ, Boutin T, Mamasoula C, Järvelin M-R, Peters A,
19 Gieger C, Lakatta EG, Cucca F, Hui J, Knekt P, Enroth S, De Borst MH, Polašek O,
20 Concas MP, Catamo E, Cocca M, Li-Gao R, Hofer E, Schmidt H, Spedicati B,
21 Waldenberger M, Strachan DP, Laan M, Teumer A, Dörr M, Gudnason V, Cook JP,
22 Ruggiero D, Kolcic I, Boerwinkle E, Traglia M, Lehtimäki T, Raitakari OT, Johnson AD,
23 Newton-Cheh C, Brown MJ, Dominiczak AF, Sever PJ, Poulter N, Chambers JC, Elosua
24 R, Siscovick D, Esko T, Metspalu A, Strawbridge RJ, Laakso M, Hamsten A, Hottenga J-

1 J, de Geus E, Morris AD, Palmer CNA, Nolte IM, Milaneschi Y, Marten J, Wright A,
2 Zeggini E, Howson JMM, O'Donnell CJ, Spector T, Nalls MA, Simonsick EM, Liu Y, van
3 Duijn CM, Butterworth AS, Danesh JN, Menni C, Wareham NJ, Khaw K-T, Sun YV,
4 Wilson PWF, Cho K, Visscher PM, Denny JC, Levy D, Edwards TL, Munroe PB, Snieder
5 H and Warren HR (2024) Genome-wide analysis in over 1 million individuals of
6 European ancestry yields improved polygenic risk scores for blood pressure traits.
7 *Nature Genetics* 56(5), 778–791. <https://doi.org/10.1038/s41588-024-01714-w>.

8 Kolifarhood G, Daneshpour M, Hadaegh F, Sabour S, Mozafar Saadati H, Akbar Haghdoost A,
9 Akbarzadeh M, Sedaghati-Khayat B and Khosravi N (2019) Heritability of blood
10 pressure traits in diverse populations: a systematic review and meta-analysis. *Journal*
11 *of Human Hypertension* 33(11), 775–785. [https://doi.org/10.1038/s41371-019-0253-](https://doi.org/10.1038/s41371-019-0253-4)
12 4.

13 Kurki MI, Karjalainen J, Palta P, Sipilä TP, Kristiansson K, Donner KM, Reeve MP, Laivuori H,
14 Aavikko M, Kaunisto MA, Loukola A, Lahtela E, Mattsson H, Laiho P, Della Briotta
15 Parolo P, Lehisto AA, Kanai M, Mars N, Rämö J, Kiiskinen T, Heyne HO, Veerapen K,
16 Rüeger S, Lemmelä S, Zhou W, Ruotsalainen S, Pärn K, Hiekkalinna T, Koskelainen S,
17 Paajanen T, Llorens V, Gracia-Tabuenca J, Siirtola H, Reis K, Elnahas AG, Sun B, Foley
18 CN, Aalto-Setälä K, Alasoo K, Arvas M, Auro K, Biswas S, Bizaki-Vallaskangas A,
19 Carpen O, Chen C-Y, Dada OA, Ding Z, Ehm MG, Eklund K, Färkkilä M, Finucane H,
20 Ganna A, Ghazal A, Graham RR, Green EM, Hakanen A, Hautalahti M, Hedman ÅK,
21 Hiltunen M, Hinttala R, Hovatta I, Hu X, Huertas-Vazquez A, Huilaja L, Hunkapiller J,
22 Jacob H, Jensen J-N, Joensuu H, John S, Julkunen V, Jung M, Juntila J, Kaarniranta K,
23 Kähönen M, Kajanne R, Kallio L, Kälviäinen R, Kaprio J, Kerimov N, Kettunen J,
24 Kilpeläinen E, Kilpi T, Klinger K, Kosma V-M, Kuopio T, Kurra V, Laisk T, Laukkanen J,

1 Lawless N, Liu A, Longerich S, Mägi R, Mäkelä J, Mäkitie A, Malarstig A, Mannermaa
2 A, Maranville J, Matakidou A, Meretoja T, Mozaffari SV, Niemi MEK, Niemi M,
3 Niiranen T, O'Donnell CJ, Obeidat M, Okafo G, Ollila HM, Palomäki A, Palotie T,
4 Partanen J, Paul DS, Pelkonen M, Pendergrass RK, Petrovski S, Pitkäranta A, Platt A,
5 Pulford D, Punkka E, Pussinen P, Raghavan N, Rahimov F, Rajpal D, Renaud NA, Riley-
6 Gillis B, Rodosthenous R, Saarentaus E, Salminen A, Salminen E, Salomaa V,
7 Schleutker J, Serpi R, Shen H, Siegel R, Silander K, Siltanen S, Soini S, Soininen H, Sul
8 JH, Tachmazidou I, Tasanen K, Tienari P, Toppila-Salmi S, Tukiainen T, Tuomi T,
9 Turunen JA, Ulirsch JC, Vaura F, Virolainen P, Waring J, Waterworth D, Yang R, Nelis
10 M, Reigo A, Metspalu A, Milani L, Esko T, Fox C, Havulinna AS, Perola M, Ripatti S,
11 Jalanko A, Laitinen T, Mäkelä TP, Plenge R, McCarthy M, Runz H, Daly MJ and Palotie
12 A (2023) FinnGen provides genetic insights from a well-phenotyped isolated
13 population. *Nature* 613(7944), 508–518. [https://doi.org/10.1038/s41586-022-](https://doi.org/10.1038/s41586-022-05473-8)
14 [05473-8](https://doi.org/10.1038/s41586-022-05473-8).
15 Lerman LO, Kurtz TW, Touyz RM, Ellison DH, Chade AR, Crowley SD, Mattson DL, Mullins JJ,
16 Osborn J, Eirin A, Reckelhoff JF, Iadecola C and Coffman TM (2019) Animal Models of
17 Hypertension: A Scientific Statement From the American Heart Association.
18 *Hypertension (Dallas, Tex. : 1979)* 73(6), e87.
19 <https://doi.org/10.1161/HYP.0000000000000090>.
20 Levy D, DeStefano AL, Larson MG, O'Donnell CJ, Lifton RP, Gavras H, Cupples LA and Myers
21 RH (2000) Evidence for a Gene Influencing Blood Pressure on Chromosome 17.
22 *Hypertension*. <https://doi.org/10.1161/01.HYP.36.4.477>.
23 Levy D, Ehret GB, Rice K, Verwoert GC, Launer LJ, Dehghan A, Glazer NL, Morrison AC,
24 Johnson AD, Aspelund T, Aulchenko Y, Lumley T, Köttgen A, Vasan RS, Rivadeneira F,

- 1 Eiriksdottir G, Guo X, Arking DE, Mitchell GF, Mattace-Raso FUS, Smith AV, Taylor K,
2 Scharpf RB, Hwang S-J, Sijbrands EJG, Bis J, Harris TB, Ganesh SK, O'Donnell CJ,
3 Hofman A, Rotter JI, Coresh J, Benjamin EJ, Uitterlinden AG, Heiss G, Fox CS,
4 Witteman JCM, Boerwinkle E, Wang TJ, Gudnason V, Larson MG, Chakravarti A, Psaty
5 BM and Duijn CM van (2009) Genome-wide association study of blood pressure and
6 hypertension. *Nature Genetics* 41(6), 677. <https://doi.org/10.1038/ng.384>.
- 7 Lewis CM and Vassos E (2020) Polygenic risk scores: from research tools to clinical
8 instruments. *Genome Medicine* 12(1), 1–11. [https://doi.org/10.1186/s13073-020-](https://doi.org/10.1186/s13073-020-00742-5)
9 00742-5.
- 10 Li Y-H, Zhang G-G and Wang N (2017) Systematic Characterization and Prediction of Human
11 Hypertension Genes. *Hypertension*.
12 <https://doi.org/10.1161/HYPERTENSIONAHA.116.08573>.
- 13 Mancia G, Kreutz R, Brunström M, Burnier M, Grassi G, Januszewicz A, Muiesan ML, Tsioufis
14 K, Agabiti-Rosei E, Algharably EAE, Azizi M, Benetos A, Borghi C, Hitij JB, Cifkova R,
15 Coca A, Cornelissen V, Cruickshank JK, Cunha PG, Danser AHJ, Pinho RM de, Delles C,
16 Dominiczak AF, Dorobantu M, Doumas M, Fernández-Alfonso MS, Halimi J-M, Járαι Z,
17 Jelaković B, Jordan J, Kuznetsova T, Laurent S, Lovic D, Lurbe E, Mahfoud F, Manolis
18 A, Miglinas M, Narkiewicz K, Niiranen T, Palatini P, Parati G, Pathak A, Persu A,
19 Polonia J, Redon J, Sarafidis P, Schmieder R, Spronck B, Stabouli S, Stergiou G, Taddei
20 S, Thomopoulos C, Tomaszewski M, Van de Borne P, Wanner C, Weber T, Williams B,
21 Zhang Z-Y and Kjeldsen SE (2023) 2023 ESH Guidelines for the management of
22 arterial hypertension The Task Force for the management of arterial hypertension of
23 the European Society of Hypertension: Endorsed by the International Society of

- 1 Hypertension (ISH) and the European Renal Association (ERA). *Journal of*
2 *Hypertension* 41(12), 1874. <https://doi.org/10.1097/HJH.0000000000003480>.
- 3 Masi S, Dalpiaz H and Borghi C (2024) Gene editing of angiotensin for blood pressure
4 management. *International Journal of Cardiology Cardiovascular Risk and Prevention*
5 23, 200323. <https://doi.org/10.1016/j.ijcrp.2024.200323>.
- 6 McEvoy JW, McCarthy CP, Bruno RM, Brouwers S, Canavan MD, Ceconi C, Christodorescu
7 RM, Daskalopoulou SS, Ferro CJ, Gerdtz E, Hanssen H, Harris J, Lauder L, McManus
8 RJ, Molloy GJ, Rahimi K, Regitz-Zagrosek V, Rossi GP, Sandset EC, Scheenaerts B,
9 Staessen JA, Uchmanowicz I, Volterrani M, Touyz RM, Group ESD, Abreu A, Olsen
10 MH, Ambrosetti M, Androulakis E, Bang LE, Bech JN, Borger MA, Boutouyrie P,
11 Bronze L, Buccheri S, Dalmau R, De Pablo Zarzosa MC, Delles C, Fiuza MM, Gabulova
12 R, Haugen BO, Heiss C, Ibanez B, James S, Kapil V, Kayikçioğlu M, Køber L, Koskinas
13 KC, Locati ET, MacDonald S, Mihailidou AS, Mihaylova B, Mindham R, Mortensen MB,
14 Nardai S, Neubeck L, Nielsen JC, Nilsson PM, Pasquet AA, Pedro MM, Prescott E,
15 Rakisheva A, Rietzschel E, Rocca B, Rossello X, Schmid J-P, Shantsila E, Sudano I,
16 Timóteo AT, Tsigoulis G, Ungar A, Vaartjes I, Visseren F, Voeller H, Vrints C,
17 Witkowski A, Zennaro M-C, Zeppenfeld K, Shuka N, Laredj N, Pavo N, Mirzoyev U,
18 van de Borne P, Sokolović Š, Postadzhiyan A, Samardzic J, Agathangelou P, Widimsky
19 J, Olsen MH, El-Kilany WM, Pauklin P, Laukkanen JA, Boulestreau R,
20 Tsinamdzgvishvili B, Kintscher U, Marketou M, Páll D, Hrafnkelsdóttir ÞJ, Dolan E,
21 Wolak T, Bilo G, Tundubayeva MK, Mirrakhimov E, Trusinskis K, Kiwan G, Msalem O,
22 Badariéné J, Banu C-A, Balbi MM, Caraus A, Boskovic A, Mouine N, Vromen T,
23 Bosevski M, Midtbø HB, Doroszko A, Dores H, Badila E, Bini R, Simić DV, Fras Z,
24 Mazón P, Spaak J, Burkard T, Barakat E, Abdessalem S, Gunes Y, Sirenko YM, Brady

1 AJB and Khamidullaeva GA (2024) 2024 ESC Guidelines for the management of
2 elevated blood pressure and hypertension: Developed by the task force on the
3 management of elevated blood pressure and hypertension of the European Society
4 of Cardiology (ESC) and endorsed by the European Society of Endocrinology (ESE)
5 and the European Stroke Organisation (ESO). *European Heart Journal* 45(38), 3912–
6 4018. <https://doi.org/10.1093/eurheartj/ehae178>.

7 Murray CJL, Aravkin AY, Zheng P, Abbafati C, Abbas KM, Abbasi-Kangevari M, Abd-Allah F,
8 Abdelalim A, Abdollahi M, Abdollahpour I, Abegaz KH, Abolhassani H, Aboyans V,
9 Abreu LG, Abrigo MRM, Abualhasan A, Abu-Raddad LJ, Abushouk AI, Adabi M,
10 Adekanmbi V, Adeoye AM, Adetokunboh OO, Adham D, Advani SM, Agarwal G,
11 Aghamir SMK, Agrawal A, Ahmad T, Ahmadi K, Ahmadi M, Ahmadi H, Ahmed MB,
12 Akalu TY, Akinyemi RO, Akinyemiju T, Akombi B, Akunna CJ, Alahdab F, Al-Aly Z, Alam
13 K, Alam S, Alam T, Alanezi FM, Alanzi TM, Alemu B wassihun, Alhabib KF, Ali M, Ali S,
14 Alicandro G, Alinia C, Alipour V, Alizade H, Aljunid SM, Alla F, Allebeck P, Almasi-
15 Hashiani A, Al-Mekhlafi HM, Alonso J, Altirkawi KA, Amini-Rarani M, Amiri F, Amugsi
16 DA, Ancuceanu R, Anderlini D, Anderson JA, Andrei CL, Andrei T, Angus C, Anjomshoa
17 M, Ansari F, Ansari-Moghaddam A, Antonazzo IC, Antonio CAT, Antony CM,
18 Antriyandarti E, Anvari D, Anwer R, Appiah SCY, Arabloo J, Arab-Zozani M, Ariani F,
19 Armoon B, Ärnlov J, Arzani A, Asadi-Aliabadi M, Asadi-Pooya AA, Ashbaugh C,
20 Assmus M, Atafar Z, Atnafu DD, Atout MMW, Ausloos F, Ausloos M, Quintanilla BPA,
21 Ayano G, Ayanore MA, Azari S, Azarian G, Azene ZN, Badawi A, Badiye AD, Bahrami
22 MA, Bakhshaei MH, Bakhtiari A, Bakkannavar SM, Baldasseroni A, Ball K, Ballew SH,
23 Balzi D, Banach M, Banerjee SK, Bante AB, Baraki AG, Barker-Collo SL, Bärnighausen
24 TW, Barrero LH, Barthelemy CM, Barua L, Basu S, Baune BT, Bayati M, Becker JS, Bedi

1 N, Beghi E, Béjot Y, Bell ML, Bennitt FB, Bensenor IM, Berhe K, Berman AE,
2 Bhagavathula AS, Bhageerathy R, Bhala N, Bhandari D, Bhattacharyya K, Bhutta ZA,
3 Bijani A, Bikbov B, Sayeed MSB, Biondi A, Birihaane BM, Bisignano C, Biswas RK, Bitew
4 H, Bohlouli S, Bohluli M, Boon-Dooley AS, Borges G, Borzì AM, Borzouei S, Bosetti C,
5 Boufous S, Braithwaite D, Breitborde NJK, Breitner S, Brenner H, Briant PS, Briko AN,
6 Briko NI, Britton GB, Bryazka D, Bumgarner BR, Burkart K, Burnett RT, Nagaraja SB,
7 Butt ZA, Santos FLC dos, Cahill LE, Cámara LLA, Campos-Nonato IR, Cárdenas R,
8 Carreras G, Carrero JJ, Carvalho F, Castaldelli-Maia JM, Castañeda-Orjuela CA,
9 Castelpietra G, Castro F, Causey K, Cederroth CR, Cercy KM, Cerin E, Chandan JS,
10 Chang K-L, Charlson FJ, Chattu VK, Chaturvedi S, Cherbuin N, Chimed-Ochir O, Cho
11 DY, Choi J-YJ, Christensen H, Chu D-T, Chung MT, Chung S-C, Cicuttini FM, Ciobanu
12 LG, Cirillo M, Classen TKD, Cohen AJ, Compton K, Cooper OR, Costa VM, Cousin E,
13 Cowden RG, Cross DH, Cruz JA, Dahlawi SMA, Damasceno AAM, Damiani G, Dandona
14 L, Dandona R, Dangel WJ, Danielsson A-K, Dargan PI, Darwesh AM, Daryani A, Das JK,
15 Gupta RD, Neves J das, Dávila-Cervantes CA, Davitoiu DV, Leo DD, Degenhardt L,
16 DeLang M, Dellavalle RP, Demeke FM, Demoz GT, Demsie DG, Denova-Gutiérrez E,
17 Dervenis N, Dhungana GP, Dianatinasab M, Silva DD da, Diaz D, Forooshani ZSD,
18 Djalalinia S, Do HT, Dokova K, Dorostkar F, Doshmangir L, Driscoll TR, Duncan BB,
19 Duraes AR, Eagan AW, Edvardsson D, Nahas NE, Sayed IE, Tantawi ME, Elbarazi I,
20 Elgendy IY, El-Jaafary SI, Elyazar IR, Emmons-Bell S, Erskine HE, Eskandarieh S,
21 Esmaeilnejad S, Esteghamati A, Estep K, Etemadi A, Etisso AE, Fanzo J, Farahmand M,
22 Fareed M, Faridnia R, Farioli A, Faro A, Faruque M, Farzadfar F, Fattahi N, Fazlzadeh
23 M, Feigin VL, Feldman R, Fereshtehnejad S-M, Fernandes E, Ferrara G, Ferrari AJ,
24 Ferreira ML, Filip I, Fischer F, Fisher JL, Flor LS, Foigt NA, Folleyan MO, Fomenkov AA,

1 Force LM, Foroutan M, Franklin RC, Freitas M, Fu W, Fukumoto T, Furtado JM, Gad
2 MM, Gakidou E, Gallus S, Garcia-Basteiro AL, Gardner WM, Geberemariam BS,
3 Gebreslassie AAAA, Geremew A, Hayoon AG, Gething PW, Ghadimi M, Ghadiri K,
4 Ghaffarifar F, Ghafourifard M, Ghamari F, Ghashghaee A, Ghiasvand H, Ghith N,
5 Gholamian A, Ghosh R, Gill PS, Ginindza TGG, Giussani G, Gnedovskaya EV,
6 Goharinezhad S, Gopalani SV, Gorini G, Goudarzi H, Goulart AC, Greaves F, Grivna M,
7 Grosso G, Gubari MIM, Gugnani HC, Guimarães RA, Guled RA, Guo G, Guo Y, Gupta
8 R, Gupta T, Haddock B, Hafezi-Nejad N, Hafiz A, Haj-Mirzaian A, Haj-Mirzaian A, Hall
9 BJ, Halvaei I, Hamadeh RR, Hamidi S, Hammer MS, Hankey GJ, Haririan H, Haro JM,
10 Hasaballah AI, Hasan MM, Hasanpoor E, Hashi A, Hassanipour S, Hassankhani H,
11 Havmoeller RJ, Hay SI, Hayat K, Heidari G, Heidari-Soureshjani R, Henrikson HJ,
12 Herbert ME, Herteliu C, Heydarpour F, Hird TR, Hoek HW, Holla R, Hoogar P,
13 Hosgood HD, Hossain N, Hosseini M, Hosseinzadeh M, Hostiuc M, Hostiuc S, Househ
14 M, Hsairi M, Hsieh VC, Hu G, Hu K, Huda TM, Humayun A, Huynh CK, Hwang B-F,
15 Iannucci VC, Ibitoye SE, Ikeda N, Ikuta KS, Ilesanmi OS, Ilic IM, Ilic MD, Inbaraj LR,
16 Ippolito H, Iqbal U, Irvani SSN, Irvine CMS, Islam MM, Islam SMS, Iso H, Ivers RQ, Iwu
17 CCD, Iwu CJ, Iyamu IO, Jaafari J, Jacobsen KH, Jafari H, Jafarinia M, Jahani MA,
18 Jakovljevic M, Jalilian F, James SL, Janjani H, Javaheri T, Javidnia J, Jeemon P, Jenabi
19 E, Jha RP, Jha V, Ji JS, Johansson L, John O, John-Akinola YO, Johnson CO, Jonas JB,
20 Joukar F, Jozwiak JJ, Jürisson M, Kabir A, Kabir Z, Kalani H, Kalani R, Kalankesh LR,
21 Kalhor R, Kanchan T, Kapoor N, Martin BK, Karch A, Karim MA, Kassa GM, Katikireddi
22 SV, Kayode GA, Karyani AK, Keiyoro PN, Keller C, Kemmer L, Kendrick PJ, Khalid N,
23 Khammarnia M, Khan EA, Khan M, Khatab K, Khater MM, Khatib MN, Khayamzadeh
24 M, Khazaei S, Kieling C, Kim YJ, Kimokoti RW, Kisa A, Kisa S, Kivimäki M, Knibbs LD,

1 Knudsen AKS, Kocarnik JM, Kochhar S, Kopec JA, Korshunov VA, Koul PA, Koyanagi A,
2 Kraemer MUG, Krishan K, Krohn KJ, Kromhout H, Defo BK, Kumar GA, Kumar V,
3 Kurmi OP, Kusuma D, Vecchia CL, Lacey B, Lal DK, Laloo R, Lallukka T, Lami FH,
4 Landires I, Lang JJ, Langan SM, Larsson AO, Lasrado S, Lauriola P, Lazarus JV, Lee PH,
5 Lee SWH, LeGrand KE, Leigh J, Leonardi M, Lescinsky H, Leung J, Levi M, Li S, Lim L-L,
6 Linn S, Liu S, Liu S, Liu Y, Lo J, Lopez AD, Lopez JCF, Lopukhov PD, Lorkowski S, Lotufo
7 PA, Lu A, Lugo A, Maddison ER, Mahasha PW, Mahdavi MM, Mahmoudi M, Majeed
8 A, Maleki A, Maleki S, Malekzadeh R, Malta DC, Mamun AA, Manda AL, Manguerra
9 H, Mansour-Ghanaei F, Mansouri B, Mansournia MA, Herrera AMM, Maravilla JC,
10 Marks A, Martin RV, Martini S, Martins-Melo FR, Masaka A, Masoumi SZ, Mathur
11 MR, Matsushita K, Maulik PK, McAlinden C, McGrath JJ, McKee M, Mehndiratta MM,
12 Mehri F, Mehta KM, Memish ZA, Mendoza W, Menezes RG, Mengesha EW, Mereke
13 A, Mereta ST, Meretoja A, Meretoja TJ, Mestrovic T, Miazgowski B, Miazgowski T,
14 Michalek IM, Miller TR, Mills EJ, Mini GK, Miri M, Mirica A, Mirrakhimov EM, Mirzaei
15 H, Mirzaei M, Mirzaei R, Mirzaei-Alavijeh M, Misganaw AT, Mithra P, Moazen B,
16 Mohammad DK, Mohammad Y, Mezerji NMG, Mohammadian-Hafshejani A,
17 Mohammadifard N, Mohammadpourhodki R, Mohammed AS, Mohammed H,
18 Mohammed JA, Mohammed S, Mokdad AH, Molokhia M, Monasta L, Mooney MD,
19 Moradi G, Moradi M, Moradi-Lakeh M, Moradzadeh R, Moraga P, Morawska L,
20 Morgado-da-Costa J, Morrison SD, Mosapour A, Mosser JF, Mouodi S, Mousavi SM,
21 Khaneghah AM, Mueller UO, Mukhopadhyay S, Mullany EC, Musa KI, Muthupandian
22 S, Nabhan AF, Naderi M, Nagarajan AJ, Nagel G, Naghavi M, Naghshtabrizi B,
23 Naimzada MD, Najafi F, Nangia V, Nansseu JR, Naserbakht M, Nayak VC, Negoï I,
24 Ngunjiri JW, Nguyen CT, Nguyen HLT, Nguyen M, Nigatu YT, Nikbakhsh R, Nixon MR,

1 Nnaji CA, Nomura S, Norrving B, Noubiap JJ, Nowak C, Nunez-Samudio V, Oțoiu A,
2 Oancea B, Odell CM, Ogbo FA, Oh I-H, Okunga EW, Oladnabi M, Olagunju AT,
3 Olusanya BO, Olusanya JO, Omer MO, Ong KL, Onwujekwe OE, Orpana HM, Ortiz A,
4 Osarenotor O, Osei FB, Ostroff SM, Otstavnov N, Otstavnov SS, Øverland S, Owolabi
5 MO, A MP, Padubidri JR, Palladino R, Panda-Jonas S, Pandey A, Parry CDH, Pasovic M,
6 Pasupula DK, Patel SK, Pathak M, Patten SB, Patton GC, Toroudi HP, Peden AE,
7 Pennini A, Pepito VCF, Peprah EK, Pereira DM, Pesudovs K, Pham HQ, Phillips MR,
8 Piccinelli C, Pilz TM, Piradov MA, Pirsaeheb M, Plass D, Polinder S, Polkinghorne KR,
9 Pond CD, Postma MJ, Pourjafar H, Pourmalek F, Poznańska A, Prada SI, Prakash V,
10 Pribadi DRA, Pupillo E, Syed ZQ, Rabiee M, Rabiee N, Radfar A, Rafiee A, Raggi A,
11 Rahman MA, Rajabpour-Sanati A, Rajati F, Rakovac I, Ram P, Ramezanzadeh K,
12 Ranabhat CL, Rao PC, Rao SJ, Rashedi V, Rathi P, Rawaf DL, Rawaf S, Rawal L,
13 Rawassizadeh R, Rawat R, Razo C, Redford SB, Reiner RC, Reitsma MB, Remuzzi G,
14 Renjith V, Renzaho AMN, Resnikoff S, Rezaei N, Rezaei N, Rezapour A, Rhinehart P-A,
15 Riahi SM, Ribeiro DC, Ribeiro D, Rickard J, Rivera JA, Roberts NLS, Rodríguez-Ramírez
16 S, Roeber L, Ronfani L, Room R, Roshandel G, Roth GA, Rothenbacher D, Rubagotti E,
17 Rwegerera GM, Sabour S, Sachdev PS, Saddik B, Sadeghi E, Sadeghi M, Saeedi R,
18 Moghaddam SS, Safari Y, Safi S, Safiri S, Sagar R, Sahebkar A, Sajadi SM, Salam N,
19 Salamati P, Salem H, Salem MRR, Salimzadeh H, Salman OM, Salomon JA, Samad Z,
20 Kafil HS, Sambala EZ, Samy AM, Sanabria J, Sánchez-Pimienta TG, Santomauro DF,
21 Santos IS, Santos JV, Santric-Milicevic MM, Saraswathy SYI, Sarmiento-Suárez R,
22 Sarrafzadegan N, Sartorius B, Sarveazad A, Sathian B, Sathish T, Sattin D, Saxena S,
23 Schaeffer LE, Schiavolin S, Schlaich MP, Schmidt MI, Schutte AE, Schwebel DC,
24 Schwendicke F, Senbeta AM, Senthilkumaran S, Sepanlou SG, Serdar B, Serre ML,

1 Shadid J, Shafaat O, Shahabi S, Shaheen AA, Shaikh MA, Shalash AS, Shams-
2 Beyranvand M, Shamsizadeh M, Sharafi K, Sheikh A, Sheikhtaheri A, Shibuya K, Shield
3 KD, Shigematsu M, Shin JI, Shin M-J, Shiri R, Shirkoohi R, Shuval K, Siabani S,
4 Sierpinski R, Sigfusdottir ID, Sigurvinsdottir R, Silva JP, Simpson KE, Singh JA, Singh P,
5 Skiadaresi E, Skou ST, Skryabin VY, Smith EUR, Soheili A, Soltani S, Soofi M, Sorensen
6 RJD, Soriano JB, Sorrie MB, Soshnikov S, Soyiri IN, Spencer CN, Spotin A,
7 Sreeramareddy CT, Srinivasan V, Stanaway JD, Stein C, Stein DJ, Steiner C, Stockfelt L,
8 Stokes MA, Straif K, Stubbs JL, Sufiyan MB, Suleria HAR, Abdulkader RS, Sulo G,
9 Sultan I, Szumowski Ł, Tabarés-Seisdedos R, Tabb KM, Tabuchi T, Taherkhani A,
10 Tajdini M, Takahashi K, Takala JS, Tamiru AT, Taveira N, Tehrani-Banihashemi A,
11 Temsah M-H, Tesema GA, Tessema ZT, Thurston GD, Titova MV, Tohidinik HR, Tonelli
12 M, Topor-Madry R, Topouzis F, Torre AE, Touvier M, Tovani-Palone MRR, Tran BX,
13 Travillian R, Tsatsakis A, Car LT, Tyrovolas S, Uddin R, Umeokonkwo CD, Unnikrishnan
14 B, Upadhyay E, Vacante M, Valdez PR, Donkelaar A van, Vasankari TJ, Vasseghian Y,
15 Veisani Y, Venketasubramanian N, Violante FS, Vlassov V, Vollset SE, Vos T, Vukovic
16 R, Waheed Y, Wallin MT, Wang Y, Wang Y-P, Watson A, Wei J, Wei MYW, Weintraub
17 RG, Weiss J, Werdecker A, West JJ, Westerman R, Whisnant JL, Whiteford HA, Wiens
18 KE, Wolfe CDA, Wozniak SS, Wu A-M, Wu J, Hanson SW, Xu G, Xu R, Yadgir S, Jabbari
19 SHY, Yamagishi K, Yaminfirooz M, Yano Y, Yaya S, Yazdi-Feyzabadi V, Yeheyis TY,
20 Yilgwan CS, Yilma MT, Yip P, Yonemoto N, Younis MZ, Younker TP, Yousefi B, Yousefi
21 Z, Yousefinezhadi T, Yousuf AY, Yu C, Yusefzadeh H, Moghadam TZ, Zamani M,
22 Zamanian M, Zandian H, Zastrozhin MS, Zhang Y, Zhang Z-J, Zhao JT, Zhao X-JG, Zhao
23 Y, Zhou M, Ziapour A, Zimsen SRM, Brauer M, Afshin A and Lim SS (2020) Global
24 burden of 87 risk factors in 204 countries and territories, 1990–2019: a systematic

1 analysis for the Global Burden of Disease Study 2019. *The Lancet* 396(10258), 1223–
2 1249. [https://doi.org/10.1016/S0140-6736\(20\)30752-2](https://doi.org/10.1016/S0140-6736(20)30752-2).

3 Nazarzadeh M, Pinho-Gomes A-C, Byrne KS, Canoy D, Raimondi F, Solares JRA, Otto CM and
4 Rahimi K (2019) Systolic Blood Pressure and Risk of Valvular Heart Disease: A
5 Mendelian Randomization Study. *JAMA Cardiology* 4(8), 788–795.
6 <https://doi.org/10.1001/jamacardio.2019.2202>.

7 Newton-Cheh C, Johnson T, Gateva V, Tobin MD, Bochud M, Coin L, Najjar SS, Zhao JH,
8 Heath SC, Eyheramendy S, Papadakis K, Voight BF, Scott LJ, Zhang F, Farrall M,
9 Tanaka T, Wallace C, Chambers JC, Khaw K-T, Nilsson P, van der Harst P, Polidoro S,
10 Grobbee DE, Onland-Moret NC, Bots ML, Wain LV, Elliott KS, Teumer A, Luan J, Lucas
11 G, Kuusisto J, Burton PR, Hadley D, McArdle WL, Brown M, Dominiczak A, Newhouse
12 SJ, Samani NJ, Webster J, Zeggini E, Beckmann JS, Bergmann S, Lim N, Song K,
13 Vollenweider P, Waeber G, Waterworth DM, Yuan X, Groop L, Orho-Melander M,
14 Allione A, Di Gregorio A, Guarrera S, Panico S, Ricceri F, Romanazzi V, Sacerdote C,
15 Vineis P, Barroso I, Sandhu MS, Luben RN, Crawford GJ, Jousilahti P, Perola M,
16 Boehnke M, Bonnycastle LL, Collins FS, Jackson AU, Mohlke KL, Stringham HM, Valle
17 TT, Willer CJ, Bergman RN, Morken MA, Döring A, Gieger C, Illig T, Meitinger T, Org E,
18 Pfeufer A, Wichmann HE, Kathiresan S, Marrugat J, O'Donnell CJ, Schwartz SM,
19 Siscovick DS, Subirana I, Freimer NB, Hartikainen A-L, McCarthy MI, O'Reilly PF,
20 Peltonen L, Pouta A, de Jong PE, Snieder H, van Gilst WH, Clarke R, Goel A, Hamsten
21 A, Peden JF, Seedorf U, Syvänen A-C, Tognoni G, Lakatta EG, Sanna S, Scheet P,
22 Schlessinger D, Scuteri A, Dörr M, Ernst F, Felix SB, Homuth G, Lorbeer R, Reffelmann
23 T, Rettig R, Völker U, Galan P, Gut IG, Herberg S, Lathrop GM, Zelenika D, Deloukas
24 P, Soranzo N, Williams FM, Zhai G, Salomaa V, Laakso M, Elosua R, Forouhi NG,

- 1 Völzke H, Uiterwaal CS, van der Schouw YT, Numans ME, Matullo G, Navis G,
2 Berglund G, Bingham SA, Kooner JS, Connell JM, Bandinelli S, Ferrucci L, Watkins H,
3 Spector TD, Tuomilehto J, Altshuler D, Strachan DP, Laan M, Meneton P, Wareham
4 NJ, Uda M, Jarvelin M-R, Mooser V, Melander O, Loos RJ, Elliott P, Abecasis GR,
5 Caulfield M and Munroe PB (2009) Genome-wide association study identifies eight
6 loci associated with blood pressure. *Nature Genetics* 41(6), 666–676.
7 <https://doi.org/10.1038/ng.361>.
- 8 Nicholls HL, John CR, Watson DS, Munroe PB, Barnes MR and Cabrera CP (2020) Reaching
9 the End-Game for GWAS: Machine Learning Approaches for the Prioritization of
10 Complex Disease Loci. *Frontiers in Genetics* 11, 521712.
11 <https://doi.org/10.3389/fgene.2020.00350>.
- 12 Oliveros W, Delfosse K, Lato DF, Kiriakopoulos K, Mokhtaridoost M, Said A, McMurray BJ,
13 Browning JW, Mattioli K, Meng G, Ellis J, Mital S, Melé M and Maass PG (2023)
14 Systematic characterization of regulatory variants of blood pressure genes. *Cell*
15 *Genomics* 3(7). <https://doi.org/10.1016/j.xgen.2023.100330>.
- 16 Our Future Health (n.d.). <https://ourfuturehealth.org.uk/>
- 17 Page IH (1949) PATHOGENESIS OF ARTERIAL HYPERTENSION. *Journal of the American*
18 *Medical Association* 140(5), 451–458.
19 <https://doi.org/10.1001/jama.1949.02900400005002>.
- 20 Page IH (1982) The mosaic theory 32 years later. *Hypertension (Dallas, Tex.: 1979)* 4(2), 177.
21 <https://doi.org/10.1161/01.hyp.4.2.177>.
- 22 Parcha V, Pampana A, Shetty NS, Irvin MR, Natarajan P, Lin HJ, Guo X, Rich SS, Rotter JI, Li P,
23 Oparil S, Arora G and Arora P (2022) Association of a Multiancestry Genome-Wide

- 1 Blood Pressure Polygenic Risk Score With Adverse Cardiovascular Events. *Circulation:*
2 *Genomic and Precision Medicine*. <https://doi.org/10.1161/CIRCGEN.122.003946>.
- 3 Perkovic V, Huxley R, Wu Y, Prabhakaran D and MacMahon S (2007) The Burden of Blood
4 Pressure-Related Disease. *Hypertension*.
5 <https://doi.org/10.1161/HYPERTENSIONAHA.107.095497>.
- 6 Poulter NR, Prabhakaran D and Caulfield M (2015) Hypertension. *The Lancet* 386(9995),
7 801–812. [https://doi.org/10.1016/S0140-6736\(14\)61468-9](https://doi.org/10.1016/S0140-6736(14)61468-9).
- 8 Psaty BM, O'Donnell CJ, Gudnason V, Lunetta KL, Folsom AR, Rotter JI, Uitterlinden AG,
9 Harris TB, Witteman JCM and Boerwinkle E (2009) Cohorts for Heart and Aging
10 Research in Genomic Epidemiology (CHARGE) Consortium. *Circulation:*
11 *Cardiovascular Genetics*. <https://doi.org/10.1161/CIRCGENETICS.108.829747>.
- 12 Roden DM, McLeod HL, Relling MV, Williams MS, Mensah GA, Peterson JF and Driest SLV
13 (2019) Pharmacogenomics. *The Lancet* 394(10197), 521–532.
14 [https://doi.org/10.1016/S0140-6736\(19\)31276-0](https://doi.org/10.1016/S0140-6736(19)31276-0).
- 15 Sheng X, Guan Y, Ma Z, Wu J, Liu H, Qiu C, Vitale S, Miao Z, Seasock MJ, Palmer M, Shin MK,
16 Duffin KL, Pullen SS, Edwards TL, Hellwege JN, Hung AM, Li M, Voight BF, Coffman
17 TM, Brown CD and Susztak K (2021) Mapping the genetic architecture of human
18 traits to cell types in the kidney identifies mechanisms of disease and potential
19 treatments. *Nature Genetics* 53(9), 1322–1333. [https://doi.org/10.1038/s41588-021-](https://doi.org/10.1038/s41588-021-00909-9)
20 [00909-9](https://doi.org/10.1038/s41588-021-00909-9).
- 21 Shetty NS, Pampana A, Patel N, Li P, Yerabolu K, Gaonkar M, Arora G and Arora P (2023) Sex
22 Differences in the Association of Genome-Wide Systolic Blood Pressure Polygenic
23 Risk Score With Hypertension. *Circulation: Genomic and Precision Medicine*.
24 <https://doi.org/10.1161/CIRCGEN.123.004259>.

- 1 Sun H, Hodgkinson CP, Pratt RE and Dzau VJ (2021) CRISPR/Cas9 Mediated Deletion of the
2 Angiotensinogen Gene Reduces Hypertension: A Potential for Cure? *Hypertension*.
3 <https://doi.org/10.1161/HYPERTENSIONAHA.120.16870>.
- 4 Sung YJ, Winkler TW, Fuentes L de las, Bentley AR, Brown MR, Kraja AT, Schwander K, Ntalla
5 I, Guo X, Franceschini N, Lu Y, Cheng C-Y, Sim X, Vojinovic D, Marten J, Musani SK, Li
6 C, Feitosa MF, Kilpeläinen TO, Richard MA, Noordam R, Aslibekyan S, Aschard H,
7 Bartz TM, Dorajoo R, Liu Y, Manning AK, Rankinen T, Smith AV, Tajuddin SM, Tayo
8 BO, Warren HR, Zhao W, Zhou Y, Matoba N, Sofer T, Alver M, Amini M, Boissel M,
9 Chai JF, Chen X, Divers J, Gandin I, Gao C, Giulianini F, Goel A, Harris SE, Hartwig FP,
10 Horimoto AR, Hsu F-C, Jackson AU, Kähönen M, Kasturiratne A, Kühnel B, Leander K,
11 Lee W-J, Lin K-H, Luan J 'an, McKenzie CA, Meian H, Nelson CP, Rauramaa R, Schupf
12 N, Scott RA, Sheu WH, Stančáková A, Takeuchi F, Most PJ van der, Varga TV, Wang H,
13 Wang Y, Ware EB, Weiss S, Wen W, Yanek LR, Zhang W, Zhao JH, Afaq S, Alfred T,
14 Amin N, Arking D, Aung T, Barr RG, Bielak LF, Boerwinkle E, Bottinger EP, Braund PS,
15 Brody JA, Broeckel U, Cabrera CP, Cade B, Caizheng Y, Campbell A, Canouil M,
16 Chakravarti A, Group TCNW, Chauhan G, Christensen K, Cocca M and Consortium TC-
17 K (2018) A Large-Scale Multi-ancestry Genome-wide Study Accounting for Smoking
18 Behavior Identifies Multiple Significant Loci for Blood Pressure. *American Journal of*
19 *Human Genetics* 102(3), 375. <https://doi.org/10.1016/j.ajhg.2018.01.015>.
- 20 Surendran P, Feofanova EV, Lahrouchi N, Ntalla I, Karthikeyan S, Cook J, Chen L, Mifsud B,
21 Yao C, Kraja AT, Cartwright JH, Hellwege JN, Giri A, Tragante V, Thorleifsson G, Liu DJ,
22 Prins BP, Stewart ID, Cabrera CP, Eales JM, Akbarov A, Auer PL, Bielak LF, Bis JC,
23 Braithwaite VS, Brody JA, Daw EW, Warren HR, Drenos F, Nielsen SF, Faul JD,
24 Fauman EB, Fava C, Ferreira T, Foley CN, Franceschini N, Gao H, Giannakopoulou O,

1 Giulianini F, Gudbjartsson DF, Guo X, Harris SE, Havulinna AS, Helgadottir A, Huffman
2 JE, Hwang S-J, Kanoni S, Kontto J, Larson MG, Li-Gao R, Lindström J, Lotta LA, Lu Y,
3 Luan J, Mahajan A, Malerba G, Masca NGD, Mei H, Menni C, Mook-Kanamori DO,
4 Mosen-Ansorena D, Müller-Nurasyid M, Paré G, Paul DS, Perola M, Poveda A,
5 Rauramaa R, Richard M, Richardson TG, Sepúlveda N, Sim X, Smith AV, Smith JA,
6 Staley JR, Stanáková A, Sulem P, Thériault S, Thorsteinsdottir U, Trompet S, Varga TV,
7 Velez Edwards DR, Veronesi G, Weiss S, Willems SM, Yao J, Young R, Yu B, Zhang W,
8 Zhao J-H, Zhao W, Evangelou E, Aeschbacher S, Asllanaj E, Blankenberg S,
9 Bonnycastle LL, Bork-Jensen J, Brandslund I, Braund PS, Burgess S, Cho K, Christensen
10 C, Connell J, Mutsert R de, Dominiczak AF, Dörr M, Eiriksdottir G, Farmaki A-E,
11 Gaziano JM, Grarup N, Grove ML, Hallmans G, Hansen T, Have CT, Heiss G, Jørgensen
12 ME, Jousilahti P, Kajantie E, Kamat M, Käräjämäki A, Karpe F, Koistinen HA, Kovesdy
13 CP, Kuulasmaa K, Laatikainen T, Lannfelt L, Lee I-T, Lee W-J, Linneberg A, Martin LW,
14 Moitry M, Nadkarni G, Neville MJ, Palmer CNA, Papanicolaou GJ, Pedersen O, Peters
15 J, Poulter N, Rasheed A, Rasmussen KL, Rayner NW, Mägi R, Renström F, Rettig R,
16 Rossouw J, Schreiner PJ, Sever PS, Sigurdsson EL, Skaaby T, Sun YV, Sundstrom J,
17 Thorgeirsson G, Esko T, Trabetti E, Tsao PS, Tuomi T, Turner ST, Tzoulaki I, Vaartjes I,
18 Vergnaud A-C, Willer CJ, Wilson PWF, Witte DR, Yonova-Doing E, Zhang H, Aliya N,
19 Almgren P, Amouyel P, Asselbergs FW, Barnes MR, Blakemore AI, Boehnke M, Bots
20 ML, Bottinger EP, Buring JE, Chambers JC, Chen Y-DI, Chowdhury R, Conen D, Correa
21 A, Davey Smith G, Boer RA de, Deary IJ, Dedoussis G, Deloukas P, Di Angelantonio E,
22 Elliott P, Felix SB, Ferrières J, Ford I, Fornage M, Franks PW, Franks S, Frossard P,
23 Gambaro G, Gaunt TR, Groop L, Gudnason V, Harris TB, Hayward C, Hennig BJ, Herzig
24 K-H, Ingelsson E, Tuomilehto J, Järvelin M-R, Jukema JW, Kardina SLR, Kee F, Kooner

1 JS, Kooperberg C, Launer LJ, Lind L, Loos RJF, Majumder A al S, Laakso M, McCarthy
2 MI, Melander O, Mohlke KL, Murray AD, Nordestgaard BG, Orho-Melander M,
3 Packard CJ, Padmanabhan S, Palmas W, Polasek O, Porteous DJ, Prentice AM,
4 Province MA, Relton CL, Rice K, Ridker PM, Rolandsson O, Rosendaal FR, Rotter JI,
5 Rudan I, Salomaa V, Samani NJ, Sattar N, Sheu WH-H, Smith BH, Soranzo N, Spector
6 TD, Starr JM, Sebert S, Taylor KD, Lakka TA, Timpson NJ, Tobin MD, van der Harst P,
7 van der Meer P, Ramachandran VS, Verweij N, Virtamo J, Völker U, Weir DR, Zeggini
8 E, Charchar FJ, Wareham NJ, Langenberg C, Tomaszewski M, Butterworth AS,
9 Caulfield MJ, Danesh J, Edwards TL, Holm H, Hung AM, Lindgren CM, Liu C, Manning
10 AK, Morris AP, Morrison AC, O'Donnell CJ, Psaty BM, Saleheen D, Stefansson K,
11 Boerwinkle E, Chasman DI, Levy D, Newton-Cheh C, Munroe PB and Howson JMM
12 (2020) Discovery of rare variants associated with blood pressure regulation through
13 meta-analysis of 1.3 million individuals. *Nature Genetics* 52(12), 1314–1332.
14 <https://doi.org/10.1038/s41588-020-00713-x>.

15 Takeuchi F, Isono M, Katsuya T, Yamamoto K, Yokota M, Sugiyama T, Nabika T, Fujioka A,
16 Ohnaka K, Asano H, Yamori Y, Yamaguchi S, Kobayashi S, Takayanagi R, Ogiwara T and
17 Kato N (2010) Blood Pressure and Hypertension Are Associated With 7 Loci in the
18 Japanese Population. *Circulation*.
19 <https://doi.org/10.1161/CIRCULATIONAHA.109.904664>.

20 Tang C, Ma Y, Lei X, Ding Y, Yang S and He D (2023) Hypertension linked to Alzheimer's
21 disease via stroke: Mendelian randomization. *Scientific Reports* 13(1), 1–9.
22 <https://doi.org/10.1038/s41598-023-49087-0>.

- 1 The Framingham Heart Study and the epidemiology of cardiovascular disease: a historical
2 perspective (2014) *The Lancet* 383(9921), 999–1008. [https://doi.org/10.1016/S0140-](https://doi.org/10.1016/S0140-6736(13)61752-3)
3 [6736\(13\)61752-3](https://doi.org/10.1016/S0140-6736(13)61752-3).
- 4 Thomopoulos C, Parati G and Zanchetti A (2015) Effects of blood pressure lowering on
5 outcome incidence in hypertension: 4. Effects of various classes of antihypertensive
6 drugs – Overview and meta-analyses. *Journal of Hypertension* 33(2), 195.
7 <https://doi.org/10.1097/HJH.0000000000000447>.
- 8 Verma A, Huffman JE, Rodriguez A, Conery M, Liu M, Ho Y-L, Kim Y, Heise DA, Guare L,
9 Panickan VA, Garcon H, Linares F, Costa L, Goethert I, Tipton R, Honerlaw J, Davies L,
10 Whitbourne S, Cohen J, Posner DC, Sangar R, Murray M, Wang X, Dochtermann DR,
11 Devineni P, Shi Y, Nandi TN, Assimes TL, Brunette CA, Carroll RJ, Clifford R, Duvall S,
12 Gelernter J, Hung A, Iyengar SK, Joseph J, Kember R, Kranzler H, Kripke CM, Levey D,
13 Luoh S-W, Merritt VC, Overstreet C, Deak JD, Grant SFA, Polimanti R, Roussos P,
14 Shakt G, Sun YV, Tsao N, Venkatesh S, Voloudakis G, Justice A, Begoli E, Ramoni R,
15 Tourassi G, Pyarajan S, Tsao P, O'Donnell CJ, Muralidhar S, Moser J, Casas JP, Bick
16 AG, Zhou W, Cai T, Voight BF, Cho K, Gaziano JM, Madduri RK, Damrauer S and Liao
17 KP (2024) Diversity and scale: Genetic architecture of 2068 traits in the VA Million
18 Veteran Program. *Science*. <https://doi.org/10.1126/science.adj1182>.
- 19 Wain LV, Verwoert GC, O'Reilly PF, Shi G, Johnson T, Johnson AD, Bochud M, Rice KM,
20 Henneman P, Smith AV, Ehret GB, Amin N, Larson MG, Mooser V, Hadley D, Dörr M,
21 Bis JC, Aspelund T, Esko T, Janssens ACJ, Zhao JH, Heath S, Laan M, Fu J, Pistis G, Luan
22 J, Arora P, Lucas G, Pirastu N, Pichler I, Jackson AU, Webster RJ, Zhang F, Peden JF,
23 Schmidt H, Tanaka T, Campbell H, Igl W, Milaneschi Y, Hotteng J-J, Vitart V, Chasman
24 DI, Trompet S, Bragg-Gresham JL, Alizadeh BZ, Chambers JC, Guo X, Lehtimäki T,

1 Kühnel B, Lopez LM, Polašek O, Boban M, Nelson CP, Morrison AC, Pihur V, Ganesh
2 SK, Hofman A, Kundu S, Mattace-Raso FU, Rivadeneira F, Sijbrands EJ, Uitterlinden
3 AG, Hwang S-J, Vasan RS, Wang TJ, Bergmann S, Vollenweider P, Waeber G, Laitinen
4 J, Pouta A, Zitting P, McArdle WL, Kroemer HK, Völker U, Völzke H, Glazer NL, Taylor
5 KD, Harris TB, Alavere H, Haller T, Keis A, Tammesoo M-L, Aulchenko Y, Barroso I,
6 Khaw K-T, Galan P, Hercberg S, Lathrop M, Eyheramendy S, Org E, Söber S, Lu X,
7 Nolte IM, Penninx BW, Corre T, Masciullo C, Sala C, Groop L, Voight BF and Melander
8 O (2011) Genome-wide association study identifies six new loci influencing pulse
9 pressure and mean arterial pressure. *Nature Genetics* 43(10), 1005.
10 <https://doi.org/10.1038/ng.922>.

11 Warren HR, Evangelou E, Cabrera CP, Gao H, Ren M, Mifsud B, Ntalla I, Surendran P, Liu C,
12 Cook JP, Kraja AT, Drenos F, Loh M, Verweij N, Marten J, Karaman I, Lepe MPS,
13 O'Reilly PF, Knight J, Snieder H, Kato N, He J, Tai ES, Said MA, Porteous D, Alver M,
14 Poulter N, Farrall M, Gansevoort RT, Padmanabhan S, Mägi R, Stanton A, Connell J,
15 Bakker SJL, Metspalu A, Shields DC, Thom S, Brown M, Sever P, Esko T, Hayward C,
16 van der Harst P, Saleheen D, Chowdhury R, Chambers JC, Chasman DI, Chakravarti A,
17 Newton-Cheh C, Lindgren CM, Levy D, Kooner JS, Keavney B, Tomaszewski M,
18 Samani NJ, Howson JMM, Tobin MD, Munroe PB, Ehret GB and Wain LV (2017)
19 Genome-wide association analysis identifies novel blood pressure loci and offers
20 biological insights into cardiovascular risk. *Nature Genetics* 49(3), 403–415.
21 <https://doi.org/10.1038/ng.3768>.

22 Wellcome Trust Case Control Consortium (2007) Genome-wide association study of 14,000
23 cases of seven common diseases and 3,000 shared controls. *Nature* 447(7145), 661–
24 678. <https://doi.org/10.1038/nature05911>.

- 1 Wong C (2023, November 16) UK first to approve CRISPR treatment for diseases: what you
2 need to know. [News]. <https://www.nature.com/articles/d41586-023-03590-6>
3 (accessed 11 December 2024)
- 4 Yang M-L, Xu C, Gupte T, Hoffmann TJ, Iribarren C, Zhou X and Ganesh SK (2024) Sex-specific
5 genetic architecture of blood pressure. *Nature Medicine* 30(3), 818–828.
6 <https://doi.org/10.1038/s41591-024-02858-2>.
- 7 Ye N, Jardine MJ, Oshima M, Hockham C, Heerspink HJL, Agarwal R, Bakris G, Schutte AE,
8 Arnott C, Chang TI, Górriz JL, Cannon CP, Charytan DM, Zeeuw D de, Levin A,
9 Mahaffey KW, Neal B, Pollock C, Wheeler DC, Tanna GLD, Cheng H, Perkovic V and
10 Neuen BL (2021) Blood Pressure Effects of Canagliflozin and Clinical Outcomes in
11 Type 2 Diabetes and Chronic Kidney Disease. *Circulation*.
12 <https://doi.org/10.1161/CIRCULATIONAHA.120.048740>.
- 13 Zanchetti A (1986) Platt versus Pickering: an episode in recent medical history. By J. D.
14 Swales, editor. An essay review. *Medical History* 30(1), 94.
15 <https://doi.org/10.1017/s0025727300045075>.
- 16 Zappa M, Golino M, Verdecchia P and Angeli F (2024) Genetics of Hypertension: From
17 Monogenic Analysis to GETomics. *Journal of Cardiovascular Development and*
18 *Disease* 11(5), 154. <https://doi.org/10.3390/jcdd11050154>.
19